<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34827413</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2076-3425</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain sciences</Title>
          <ISOAbbreviation>Brain Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Update on Paraneoplastic Cerebellar Degeneration.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1414</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci11111414</ELocationID>
        <Abstract>
          <AbstractText><b>Purpose of review:</b> To provide an update on paraneoplastic cerebellar degeneration (PCD), the involved antibodies and tumors, as well as management strategies. <b>Recent findings:</b> PCD represents the second most common presentation of the recently established class of immune mediated cerebellar ataxias (IMCAs). Although rare in general, PCD is one of the most frequent paraneoplastic presentations and characterized clinically by a rapidly progressive cerebellar syndrome. In recent years, several antibodies have been described in association with the clinical syndrome related to PCD; their clinical significance, however, has yet to be determined. The 2021 updated diagnostic criteria for paraneoplastic neurologic symptoms help to establish the diagnosis of PCD, direct cancer screening, and to evaluate the presence of these newly identified antibodies. Recognition of the clinical syndrome and prompt identification of a specific antibody are essential for early detection of an underlying malignancy and initiation of an appropriate treatment, which represents the best opportunity to modulate the course of the disease. As clinical symptoms can precede tumor diagnosis by years, co-occurrence of specific symptoms and antibodies should prompt continuous surveillance of the patient. <b>Summary:</b> We provide an in-depth overview on PCD, summarize recent findings related to PCD, and highlight the transformed diagnostic approach.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Loehrer</LastName>
            <ForeName>Philipp Alexander</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zieger</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simon</LastName>
            <ForeName>Ole J</ForeName>
            <Initials>OJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain Sci</MedlineTA>
        <NlmUniqueID>101598646</NlmUniqueID>
        <ISSNLinking>2076-3425</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Tr/DNER-antibody</Keyword>
        <Keyword MajorTopicYN="N">Yo-antibody</Keyword>
        <Keyword MajorTopicYN="N">immune-mediated cerebellar ataxias</Keyword>
        <Keyword MajorTopicYN="N">mGluR1-antibody</Keyword>
        <Keyword MajorTopicYN="N">onconeuronal antibodies</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic syndromes</Keyword>
      </KeywordList>
      <CoiStatement>We declare that none of the authors have competing financial or non-financial interests related to this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34827413</ArticleId>
        <ArticleId IdType="pmc">PMC8615604</ArticleId>
        <ArticleId IdType="doi">10.3390/brainsci11111414</ArticleId>
        <ArticleId IdType="pii">brainsci11111414</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mitoma H., Manto M., Hadjivassiliou M. Immune-mediated cerebellar ataxias: Clinical diagnosis and treatment based on immunological and physiological mechanisms. J. Mov. Disord. 2021;14:10–28. doi: 10.14802/jmd.20040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14802/jmd.20040</ArticleId>
            <ArticleId IdType="pmc">PMC7840241</ArticleId>
            <ArticleId IdType="pubmed">33423437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Martindale J., Shanmugarajah P., Grünewald R.A., Sarrigiannis P.G., Beauchamp N., Garrard K., Warburton R., Sanders D.S., Friend D., et al.  Causes of progressive cerebellar ataxia: Prospective evaluation of 1500 patients. J. Neurol. Neurosurg. Psychiatry. 2017;88:301–309. doi: 10.1136/jnnp-2016-314863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-314863</ArticleId>
            <ArticleId IdType="pubmed">27965395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A., Gigli G.L., Segatti S., Corazza E., Marini A., Bernardini A., Valent F., Fabris M., Curcio F., Brigo F., et al.  Epidemiology of paraneoplastic neurological syndromes: A population-based study. J. Neurol. 2020;267:26–35. doi: 10.1007/s00415-019-09544-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09544-1</ArticleId>
            <ArticleId IdType="pubmed">31552550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brouwer V. Beitrag zur kenntnis der chronishen diffusen kleinhirnerkrankungen. Neurol. Cbl. 1919;38:674–682.</Citation>
        </Reference>
        <Reference>
          <Citation>Greenlee J.E., Brashear H.R. Antibodies to cerebellar purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann. Neurol. 1983;14:609–613. doi: 10.1002/ana.410140603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410140603</ArticleId>
            <ArticleId IdType="pubmed">6360029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Vogrig A., Muñiz-Castrillo S., Antoine J.-C.G., Desestret V., Dubey D., Giometto B., Irani S.R., Joubert B., Leypoldt F., et al.  Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:e1014. doi: 10.1212/NXI.0000000000001014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000001014</ArticleId>
            <ArticleId IdType="pmc">PMC8237398</ArticleId>
            <ArticleId IdType="pubmed">34006622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loehrer P.A., Timmermann L., Pehl A., Bien C.I., Pfestroff A., Pedrosa D.J. Rhombencephalitis associated with isolated zic4-antibodies in paraneoplastic cerebellar degeneration: A case report. BMC Neurol. 2020;20:208.  doi: 10.1186/s12883-020-01788-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-020-01788-z</ArticleId>
            <ArticleId IdType="pmc">PMC7249364</ArticleId>
            <ArticleId IdType="pubmed">32450842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Rosenfeld M.R., Dalmau J. Update on neurological paraneoplastic syndromes. Curr. Opin. Oncol. 2015;27:489–495. doi: 10.1097/CCO.0000000000000222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000222</ArticleId>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pignolet B.S., Gebauer C.M., Liblau R.S. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology. 2013;2:e27384. doi: 10.4161/onci.27384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/onci.27384</ArticleId>
            <ArticleId IdType="pmc">PMC3913668</ArticleId>
            <ArticleId IdType="pubmed">24501693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Qian W., Chen Q., Yin L., Li B., Wang H. Imbalance in circulating t lymphocyte subsets contributes to hu antibody-associated paraneoplastic neurological syndromes. Cell. Immunol. 2014;290:245–250. doi: 10.1016/j.cellimm.2014.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2014.06.009</ArticleId>
            <ArticleId IdType="pubmed">25173445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., Vincent A. P/q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002;59:764–766. doi: 10.1212/WNL.59.5.764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.59.5.764</ArticleId>
            <ArticleId IdType="pubmed">12221175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A., Lang B., Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the lambert-eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989;12:496–502. doi: 10.1016/0166-2236(89)90109-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(89)90109-4</ArticleId>
            <ArticleId IdType="pubmed">2480664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coesmans M., Smitt P.A., Linden D.J., Shigemoto R., Hirano T., Yamakawa Y., van Alphen A.M., Luo C., van der Geest J.N., Kros J.M., et al.  Mechanisms underlying cerebellar motor deficits due to mglur1-autoantibodies. Ann. Neurol. 2003;53:325–336. doi: 10.1002/ana.10451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10451</ArticleId>
            <ArticleId IdType="pubmed">12601700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y.J., Safa P., Chen Y.R., Sobel R.A., Boyden E.S., Tsien R.W. Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc. Natl. Acad. Sci. USA. 2008;105:2705–2710. doi: 10.1073/pnas.0710771105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0710771105</ArticleId>
            <ArticleId IdType="pmc">PMC2268200</ArticleId>
            <ArticleId IdType="pubmed">18272482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson K., Rosenblum M.K., Kotanides H., Posner J.B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-yo antibody-positive patients. Neurology. 1992;42:1931–1937. doi: 10.1212/01.wnl.0000407657.51588.5a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000407657.51588.5a</ArticleId>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I., Graus F., Keime-Guibert F., Reñé R., Delattre J.Y., Ramón J.M., Dalmau J., Posner J.B. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-yo antibodies. Neurology. 2000;55:713–715. doi: 10.1212/WNL.55.5.713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams’ili S., Grefkens J., de Leeuw B., van den Bent M., Hooijkaas H., van der Holt B., Vecht C., Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain J. Neurol. 2003;126:1409–1418. doi: 10.1093/brain/awg133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the cns. Lancet Neurol. 2008;7:327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grativvol R.S., Cavalcante W.C.P., Castro L.H.M., Nitrini R., Simabukuro M.M. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr. Oncol. Rep. 2018;20:92. doi: 10.1007/s11912-018-0721-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-018-0721-y</ArticleId>
            <ArticleId IdType="pubmed">30415318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H., Adhikari K., Aeschlimann D., Chattopadhyay P., Hadjivassiliou M., Hampe C.S., Honnorat J., Joubert B., Kakei S., Lee J., et al.  Consensus paper: Neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:213–232. doi: 10.1007/s12311-015-0664-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-015-0664-x</ArticleId>
            <ArticleId IdType="pmc">PMC4591117</ArticleId>
            <ArticleId IdType="pubmed">25823827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducray F., Demarquay G., Graus F., Decullier E., Antoine J.C., Giometto B., Psimaras D., Delattre J.Y., Carpentier A.F., Honnorat J. Seronegative paraneoplastic cerebellar degeneration: The pns euronetwork experience. Eur. J. Neurol. 2014;21:731–735. doi: 10.1111/ene.12368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12368</ArticleId>
            <ArticleId IdType="pubmed">24471811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi E., Flanagan E.P. Antibody-mediated autoimmune diseases of the cns: Challenges and approaches to diagnosis and management. Front. Neurol. 2021;12:673339. doi: 10.3389/fneur.2021.673339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.673339</ArticleId>
            <ArticleId IdType="pmc">PMC8292678</ArticleId>
            <ArticleId IdType="pubmed">34305787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillevis Smitt P.A., Manley G.T., Posner J.B. Immunization with the paraneoplastic encephalomyelitis antigen hud does not cause neurologic disease in mice. Neurology. 1995;45:1873–1878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7477985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka K., Tanaka M., Igarashi S., Onodera O., Miyatake T., Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin. Neurol. Neurosurg. 1995;97:101–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7788964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpentier A.F., Rosenfeld M.R., Delattre J.Y., Whalen R.G., Posner J.B., Dalmau J. DNA vaccination with hud inhibits growth of a neuroblastoma in mice. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 1998;4:2819–2824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9829748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E., Dalmau J. Neuronal autoantigens—Pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 2012;8:380–390. doi: 10.1038/nrneurol.2012.99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2012.99</ArticleId>
            <ArticleId IdType="pmc">PMC3718498</ArticleId>
            <ArticleId IdType="pubmed">22710628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okano H.J., Park W.Y., Corradi J.P., Darnell R.B. The cytoplasmic purkinje onconeural antigen cdr2 down-regulates c-myc function: Implications for neuronal and tumor cell survival. Genes Dev. 1999;13:2087–2097. doi: 10.1101/gad.13.16.2087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.13.16.2087</ArticleId>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K., Kitagawa Y., Saiki S., Saiki M., Hirose G. Effect of a paraneoplastic cerebellar degeneration-associated neural protein on b-myb promoter activity. Neurobiol. Dis. 2004;15:529–533. doi: 10.1016/j.nbd.2003.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2003.11.003</ArticleId>
            <ArticleId IdType="pubmed">15056460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert M.L., Austin L.M., Darnell R.B. Detection and treatment of activated t cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 2000;47:9–17. doi: 10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I</ArticleId>
            <ArticleId IdType="pubmed">10632096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rousseau A., Benyahia B., Dalmau J., Connan F., Guillet J.G., Delattre J.Y., Choppin J. T cell response to hu-d peptides in patients with anti-hu syndrome. J. Neuro-Oncol. 2005;71:231–236. doi: 10.1007/s11060-004-1723-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-004-1723-1</ArticleId>
            <ArticleId IdType="pmc">PMC2586925</ArticleId>
            <ArticleId IdType="pubmed">15735910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aye M.M., Kasai T., Tashiro Y., Xing H.Q., Shirahama H., Mitsuda M., Suetsugu T., Tanaka K., Osame M., Izumo S. Cd8 positive t-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J. Neuroimmunol. 2009;208:136–140. doi: 10.1016/j.jneuroim.2009.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.01.017</ArticleId>
            <ArticleId IdType="pubmed">19217169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plonquet A., Gherardi R.K., Créange A., Antoine J.C., Benyahia B., Grisold W., Drlicek M., Dreyfus P., Honnorat J., Khouatra C., et al.  Oligoclonal t-cells in blood and target tissues of patients with anti-hu syndrome. J. Neuroimmunol. 2002;122:100–105. doi: 10.1016/S0165-5728(01)00452-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(01)00452-0</ArticleId>
            <ArticleId IdType="pubmed">11777548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R., Dalmau J., Posner J.B., Rosenfeld M.R. T-cell receptor analysis in anti-hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51:1146–1150. doi: 10.1212/WNL.51.4.1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.4.1146</ArticleId>
            <ArticleId IdType="pubmed">9781545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda T., Motomura M., Nakao Y., Shiraishi H., Yoshimura T., Iwanaga K., Tsujihata M., Eguchi K. Reduction of p/q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with lambert-eaton myasthenic syndrome. Ann. Neurol. 2003;53:21–28. doi: 10.1002/ana.10392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10392</ArticleId>
            <ArticleId IdType="pubmed">12509844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hildebrand M.E., Isope P., Miyazaki T., Nakaya T., Garcia E., Feltz A., Schneider T., Hescheler J., Kano M., Sakimura K., et al.  Functional coupling between mglur1 and cav3.1 t-type calcium channels contributes to parallel fiber-induced fast calcium signaling within purkinje cell dendritic spines. J. Neurosci. Off. J. Soc. Neurosci. 2009;29:9668–9682. doi: 10.1523/JNEUROSCI.0362-09.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0362-09.2009</ArticleId>
            <ArticleId IdType="pmc">PMC6666586</ArticleId>
            <ArticleId IdType="pubmed">19657020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hébert J., Riche B., Vogrig A., Muñiz-Castrillo S., Joubert B., Picard G., Rogemond V., Psimaras D., Alentorn A., Berzero G., et al.  Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in france. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e883. doi: 10.1212/NXI.0000000000000883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000883</ArticleId>
            <ArticleId IdType="pmc">PMC7455315</ArticleId>
            <ArticleId IdType="pubmed">32847939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.S., Kwon S., Ki C.S., Youn J., Cho J.W. The etiologies of chronic progressive cerebellar ataxia in a korean population. J. Clin. Neurol. 2018;14:374–380. doi: 10.3988/jcn.2018.14.3.374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2018.14.3.374</ArticleId>
            <ArticleId IdType="pmc">PMC6032000</ArticleId>
            <ArticleId IdType="pubmed">29971977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebus O., Montaut S., Monga B., Wirth T., Cheraud C., Alves Do Rego C., Zinchenko I., Carré G., Hamdaoui M., Hautecloque G., et al.  Deciphering the causes of sporadic late-onset cerebellar ataxias: A prospective study with implications for diagnostic work. J. Neurol. 2017;264:1118–1126. doi: 10.1007/s00415-017-8500-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-017-8500-5</ArticleId>
            <ArticleId IdType="pubmed">28478596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaff E., Maat P., Hulsenboom E., van den Berg R., van den Bent M., Demmers J., Lugtenburg P.J., Hoogenraad C.C., Sillevis Smitt P. Identification of delta/notch-like epidermal growth factor-related receptor as the tr antigen in paraneoplastic cerebellar degeneration. Ann. Neurol. 2012;71:815–824. doi: 10.1002/ana.23550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23550</ArticleId>
            <ArticleId IdType="pubmed">22447725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A., Tracy J.A., Pittock S.J., Parisi J.E., Klein C.J., Lennon V.A. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: The cerebellum and beyond. Arch. Neurol. 2011;68:1282–1289. doi: 10.1001/archneurol.2011.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.128</ArticleId>
            <ArticleId IdType="pubmed">21670387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Graus F., Rosenblum M.K., Posner J.B. Anti-hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine. 1992;71:59–72. doi: 10.1097/00005792-199203000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-199203000-00001</ArticleId>
            <ArticleId IdType="pubmed">1312211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann. Neurol. 2003;53:580–587. doi: 10.1002/ana.10518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10518</ArticleId>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bürk K., Wick M., Roth G., Decker P., Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J. Neurol. 2010;257:59–62. doi: 10.1007/s00415-009-5262-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5262-8</ArticleId>
            <ArticleId IdType="pubmed">19629562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L., Höftberger R., Boronat A., Saiz A., Dalmau J., Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS ONE. 2013;8:e60438.  doi: 10.1371/journal.pone.0060438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0060438</ArticleId>
            <ArticleId IdType="pmc">PMC3607586</ArticleId>
            <ArticleId IdType="pubmed">23536908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler C., Verschuuren J.J., et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Lennon V.A., Gadoth A., Pittock S.J., Flanagan E.P., Schmeling J.E., McKeon A., Klein C.J. Autoimmune crmp5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90:e103–e110. doi: 10.1212/WNL.0000000000004803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004803</ArticleId>
            <ArticleId IdType="pubmed">29222126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J., Cartalat-Carel S., Ricard D., Camdessanche J.P., Carpentier A.F., Rogemond V., Chapuis F., Aguera M., Decullier E., Duchemin A.M., et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with hu or cv2/crmp5 antibodies. J. Neurol. Neurosurg. Psychiatry. 2009;80:412–416. doi: 10.1136/jnnp.2007.138016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.138016</ArticleId>
            <ArticleId IdType="pmc">PMC2664637</ArticleId>
            <ArticleId IdType="pubmed">18931014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Z., Kryzer T.J., Griesmann G.E., Kim K., Benarroch E.E., Lennon V.A. Crmp-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity. Ann. Neurol. 2001;49:146–154. doi: 10.1002/1531-8249(20010201)49:2&lt;146::AID-ANA34&gt;3.0.CO;2-E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;146::AID-ANA34&gt;3.0.CO;2-E</ArticleId>
            <ArticleId IdType="pubmed">11220734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Keime-Guibert F., Rene R., Benyahia B., Ribalta T., Ascaso C., Escaramis G., Delattre J.Y. Anti-hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain J. Neurol. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Graus F., Villarejo A., Posner J.B., Blumenthal D., Thiessen B., Saiz A., Meneses P., Rosenfeld M.R. Clinical analysis of anti-ma2-associated encephalitis. Brain J. Neurol. 2004;127:1831–1844. doi: 10.1093/brain/awh203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh203</ArticleId>
            <ArticleId IdType="pubmed">15215214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann L.A., Jarius S., Pellkofer H.L., Schueller M., Krumbholz M., Koenig F., Johannis W., la Fougere C., Newman T., Vincent A., et al.  Anti-ma and anti-ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J. Neurol. Neurosurg. Psychiatry. 2008;79:767–773. doi: 10.1136/jnnp.2007.118588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.118588</ArticleId>
            <ArticleId IdType="pubmed">18223018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simard C., Vogrig A., Joubert B., Muñiz-Castrillo S., Picard G., Rogemond V., Ducray F., Berzero G., Psimaras D., Antoine J.C., et al.  Clinical spectrum and diagnostic pitfalls of neurologic syndromes with ri antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e699. doi: 10.1212/NXI.0000000000000699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000699</ArticleId>
            <ArticleId IdType="pmc">PMC7136048</ArticleId>
            <ArticleId IdType="pubmed">32170042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernal F., Shams’ili S., Rojas I., Sanchez-Valle R., Saiz A., Dalmau J., Honnorat J., Sillevis Smitt P., Graus F. Anti-tr antibodies as markers of paraneoplastic cerebellar degeneration and hodgkin’s disease. Neurology. 2003;60:230–234. doi: 10.1212/01.WNL.0000041495.87539.98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000041495.87539.98</ArticleId>
            <ArticleId IdType="pubmed">12552036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Jitprapaikulsan J., Bi H., Do Campo R.V., McKeon A., Pittock S.J., Engelstad J.K., Mills J.R., Klein C.J. Amphiphysin-igg autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93:e1873–e1880. doi: 10.1212/WNL.0000000000008472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008472</ArticleId>
            <ArticleId IdType="pubmed">31624089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Parisi J.E., Benarroch E.E., Mokri B., Stephan C.L., Kim K.K., Kilimann M.W., Lennon V.A. Amphiphysin autoimmunity: Paraneoplastic accompaniments. Ann. Neurol. 2005;58:96–107. doi: 10.1002/ana.20529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20529</ArticleId>
            <ArticleId IdType="pubmed">15984030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Hinson S.R., Jolliffe E.A., Zekeridou A., Flanagan E.P., Pittock S.J., Basal E., Drubach D.A., Lachance D.H., Lennon V.A., et al.  Autoimmune gfap astrocytopathy: Prospective evaluation of 90 patients in 1 year. J. Neuroimmunol. 2018;321:157–163. doi: 10.1016/j.jneuroim.2018.04.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2018.04.016</ArticleId>
            <ArticleId IdType="pubmed">29793728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A., Blanco Y., Sabater L., González F., Bataller L., Casamitjana R., Ramió-Torrentà L., Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: Diagnostic clues for this association. Brain J. Neurol. 2008;131:2553–2563. doi: 10.1093/brain/awn183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn183</ArticleId>
            <ArticleId IdType="pubmed">18687732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandel-Brehm C., Dubey D., Kryzer T.J., O’Donovan B.D., Tran B., Vazquez S.E., Sample H.A., Zorn K.C., Khan L.M., Bledsoe I.O., et al.  Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N. Engl. J. Med. 2019;381:47–54. doi: 10.1056/NEJMoa1816721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1816721</ArticleId>
            <ArticleId IdType="pmc">PMC6800027</ArticleId>
            <ArticleId IdType="pubmed">31269365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maudes E., Landa J., Muñoz-Lopetegi A., Armangue T., Alba M., Saiz A., Graus F., Dalmau J., Sabater L. Clinical significance of kelch-like protein 11 antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e666. doi: 10.1212/NXI.0000000000000666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000666</ArticleId>
            <ArticleId IdType="pmc">PMC7051195</ArticleId>
            <ArticleId IdType="pubmed">31953318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Wilson M.R., Clarkson B., Giannini C., Gandhi M., Cheville J., Lennon V.A., Eggers S., Devine M.F., Mandel-Brehm C., et al.  Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol. 2020;77:1420–1429. doi: 10.1001/jamaneurol.2020.2231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.2231</ArticleId>
            <ArticleId IdType="pmc">PMC7653501</ArticleId>
            <ArticleId IdType="pubmed">32744608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zis P., Rao D.G., Hoggard N., Sarrigiannis P.G., Hadjivassiliou M. Anti-mag associated cerebellar ataxia and response to rituximab. J. Neurol. 2018;265:115–118. doi: 10.1007/s00415-017-8675-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-017-8675-9</ArticleId>
            <ArticleId IdType="pubmed">29159464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S., Lennon V.A. New purkinje cell antibody (pca-2): Marker of lung cancer-related neurological autoimmunity. Ann. Neurol. 2000;47:297–305. doi: 10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4</ArticleId>
            <ArticleId IdType="pubmed">10716248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadoth A., Kryzer T.J., Fryer J., McKeon A., Lennon V.A., Pittock S.J. Microtubule-associated protein 1b: Novel paraneoplastic biomarker. Ann. Neurol. 2017;81:266–277. doi: 10.1002/ana.24872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24872</ArticleId>
            <ArticleId IdType="pubmed">28074593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani S.R., Pettingill P., Kleopa K.A., Schiza N., Waters P., Mazia C., Zuliani L., Watanabe O., Lang B., Buckley C., et al.  Morvan syndrome: Clinical and serological observations in 29 cases. Ann. Neurol. 2012;72:241–255. doi: 10.1002/ana.23577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23577</ArticleId>
            <ArticleId IdType="pubmed">22473710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñiz-Castrillo S., Joubert B., Elsensohn M.H., Pinto A.L., Saint-Martin M., Vogrig A., Picard G., Rogemond V., Dubois V., Tamouza R., et al.  Anti-caspr2 clinical phenotypes correlate with hla and immunological features. J. Neurol. Neurosurg. Psychiatry. 2020;91:1076–1084. doi: 10.1136/jnnp-2020-323226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-323226</ArticleId>
            <ArticleId IdType="pubmed">32651251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joubert B., Saint-Martin M., Noraz N., Picard G., Rogemond V., Ducray F., Desestret V., Psimaras D., Delattre J.Y., Antoine J.C., et al.  Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 2016;73:1115–1124. doi: 10.1001/jamaneurol.2016.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.1585</ArticleId>
            <ArticleId IdType="pubmed">27428927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin W.O., Lennon V.A., Komorowski L., Probst C., Clardy S.L., Aksamit A.J., Appendino J.P., Lucchinetti C.F., Matsumoto J.Y., Pittock S.J., et al.  Dppx potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–1803. doi: 10.1212/WNL.0000000000000991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000991</ArticleId>
            <ArticleId IdType="pmc">PMC4240433</ArticleId>
            <ArticleId IdType="pubmed">25320100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara M., Ariño H., Petit-Pedrol M., Sabater L., Titulaer M.J., Martinez-Hernandez E., Schreurs M.W., Rosenfeld M.R., Graus F., Dalmau J. Dppx antibody-associated encephalitis: Main syndrome and antibody effects. Neurology. 2017;88:1340–1348. doi: 10.1212/WNL.0000000000003796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003796</ArticleId>
            <ArticleId IdType="pmc">PMC5379928</ArticleId>
            <ArticleId IdType="pubmed">28258082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., Peles E., Buckley C., Lang B., Vincent A. Antibodies to kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, morvan’s syndrome and acquired neuromyotonia. Brain J. Neurol. 2010;133:2734–2748. doi: 10.1093/brain/awq213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awq213</ArticleId>
            <ArticleId IdType="pmc">PMC2929337</ArticleId>
            <ArticleId IdType="pubmed">20663977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadoth A., Pittock S.J., Dubey D., McKeon A., Britton J.W., Schmeling J.E., Smith A., Kotsenas A.L., Watson R.E., Lachance D.H., et al.  Expanded phenotypes and outcomes among 256 lgi1/caspr2-igg-positive patients. Ann. Neurol. 2017;82:79–92. doi: 10.1002/ana.24979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24979</ArticleId>
            <ArticleId IdType="pubmed">28628235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Chiriboga A.S., Komorowski L., Kümpfel T., Probst C., Hinson S.R., Pittock S.J., McKeon A. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. Neurology. 2016;86:1009–1013. doi: 10.1212/WNL.0000000000002476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002476</ArticleId>
            <ArticleId IdType="pmc">PMC4799712</ArticleId>
            <ArticleId IdType="pubmed">26888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski N.L., Lennon V.A., Lachance D.H., Klein C.J., Pittock S.J., McKeon A. P/q- and n-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54:220–227. doi: 10.1002/mus.25027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25027</ArticleId>
            <ArticleId IdType="pmc">PMC4940238</ArticleId>
            <ArticleId IdType="pubmed">26789908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Graus F., Honnorat J., Jarius S., Titulaer M., Manto M., Hoggard N., Sarrigiannis P., Mitoma H. Diagnostic criteria for primary autoimmune cerebellar ataxia-guidelines from an international task force on immune-mediated cerebellar ataxias. Cerebellum. 2020;19:605–610. doi: 10.1007/s12311-020-01132-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-020-01132-8</ArticleId>
            <ArticleId IdType="pmc">PMC7351847</ArticleId>
            <ArticleId IdType="pubmed">32328884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-pkc-gamma, anti-glur-delta2, anti-ca/arhgap26 and anti-vgcc. J. Neuroinflamm. 2015;12:167. doi: 10.1186/s12974-015-0357-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0357-x</ArticleId>
            <ArticleId IdType="pmc">PMC4574118</ArticleId>
            <ArticleId IdType="pubmed">26377184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Alfugham N., O’Connor K., Hinson S., Kunchok A., Lennon V.A., Komorowski L., Probst C., McKeon A. Gtpase regulator associated with focal adhesion kinase 1 (graf1) immunoglobulin-associated ataxia and neuropathy. Mov. Disord. Clin. Pract. 2020;7:904–909. doi: 10.1002/mdc3.13036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mdc3.13036</ArticleId>
            <ArticleId IdType="pmc">PMC7604666</ArticleId>
            <ArticleId IdType="pubmed">33163561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L., Sabater L., Saiz A., Serra C., Claramonte B., Graus F. Carbonic anhydrase-related protein viii: Autoantigen in paraneoplastic cerebellar degeneration. Ann. Neurol. 2004;56:575–579. doi: 10.1002/ana.20238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20238</ArticleId>
            <ArticleId IdType="pubmed">15389893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Sabater L., Velasco F., Ciordia R., Dalmau J., Graus F. Carbonic anhydrase-related protein viii antibodies and paraneoplastic cerebellar degeneration. Neuropathol. Appl. Neurobiol. 2014;40:650–653. doi: 10.1111/nan.12118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12118</ArticleId>
            <ArticleId IdType="pmc">PMC4077932</ArticleId>
            <ArticleId IdType="pubmed">24446689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prevezianou A., Tzartos J.S., Dagklis I.E., Bentenidi E., Angelopoulos P., Bostantjopoulou S. Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein viii autoantibodies. J. Neuroimmunol. 2020;344:577242. doi: 10.1016/j.jneuroim.2020.577242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2020.577242</ArticleId>
            <ArticleId IdType="pubmed">32325285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swayne A., Tjoa L., Broadley S., Dionisio S., Gillis D., Jacobson L., Woodhall M.R., McNabb A., Schweitzer D., Tsang B., et al.  Antiglycine receptor antibody related disease: A case series and literature review. Eur. J. Neurol. 2018;25:1290–1298. doi: 10.1111/ene.13721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13721</ArticleId>
            <ArticleId IdType="pmc">PMC6282944</ArticleId>
            <ArticleId IdType="pubmed">29904974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa-head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mglur1, anti-homer-3, anti-sj/itpr1 and anti-carp viii. J. Neuroinflamm. 2015;12:166. doi: 10.1186/s12974-015-0356-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0356-y</ArticleId>
            <ArticleId IdType="pmc">PMC4574226</ArticleId>
            <ArticleId IdType="pubmed">26377085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Ren H., Li L., Wang J., Fechner K., Guan H. Anti-homer-3 antibody associated cerebellar ataxia: A rare case report and literature review. J. Neuroimmunol. 2019;330:155–158. doi: 10.1016/j.jneuroim.2019.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2019.01.002</ArticleId>
            <ArticleId IdType="pubmed">30904736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuliani L., Sabater L., Saiz A., Baiges J.J., Giometto B., Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. 2007;68:239–240. doi: 10.1212/01.wnl.0000251308.79366.f9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000251308.79366.f9</ArticleId>
            <ArticleId IdType="pubmed">17224583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Sabater L., Ortega A., Dalmau J., Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol. 2013;70:506–509. doi: 10.1001/jamaneurol.2013.1955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.1955</ArticleId>
            <ArticleId IdType="pmc">PMC3723144</ArticleId>
            <ArticleId IdType="pubmed">23400636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-García R., Martínez-Hernández E., Joubert B., Petit-Pedrol M., Pajarón-Boix E., Fernández V., Salais L., Del Pozo M., Armangué T., Sabater L., et al.  Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e658. doi: 10.1212/NXI.0000000000000658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000658</ArticleId>
            <ArticleId IdType="pmc">PMC6943365</ArticleId>
            <ArticleId IdType="pubmed">31826987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mange L., Haitao R., Lixin Z., Siyuan F., Jing W., Hongzhi G. Cerebellar ataxia and myeloradiculopathy associated with ap3b2 antibody: A case report and literature review. J. Neurol. 2021;268:4163–4169. doi: 10.1007/s00415-021-10496-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-021-10496-8</ArticleId>
            <ArticleId IdType="pubmed">33988764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell R.B., Furneaux H.M., Posner J.B. Antiserum from a patient with cerebellar degeneration identifies a novel protein in purkinje cells, cortical neurons, and neuroectodermal tumors. J. Neurosci. Off. J. Soc. Neurosci. 1991;11:1224–1230. doi: 10.1523/JNEUROSCI.11-05-01224.1991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.11-05-01224.1991</ArticleId>
            <ArticleId IdType="pmc">PMC6575333</ArticleId>
            <ArticleId IdType="pubmed">1851215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-yo/cdr2, anti-nb/ap3b2, pca-2, anti-tr/dner, other antibodies, diagnostic pitfalls, summary and outlook. J. Neuroinflamm. 2015;12:168. doi: 10.1186/s12974-015-0358-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
            <ArticleId IdType="pmc">PMC4573944</ArticleId>
            <ArticleId IdType="pubmed">26377319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miske R., Gross C.C., Scharf M., Golombeck K.S., Hartwig M., Bhatia U., Schulte-Mecklenbeck A., Bönte K., Strippel C., Schöls L., et al.  Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol. Neuroimmunol. Neuroinflamm. 2017;4:e307. doi: 10.1212/NXI.0000000000000307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000307</ArticleId>
            <ArticleId IdType="pmc">PMC5141526</ArticleId>
            <ArticleId IdType="pubmed">27957508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S., Kryzer T.J., Komorowski L., Miske R., Anderson M.D., Flanagan E.P., Hinson S.R., Lennon V.A., Pittock S.J., McKeon A. Neurochondrin neurological autoimmunity. Neurol. Neuroimmunol. Neuroinflamm. 2019;6:e612. doi: 10.1212/NXI.0000000000000612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
            <ArticleId IdType="pmc">PMC6745726</ArticleId>
            <ArticleId IdType="pubmed">31511329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Ren H., Fang F., Yang X., Wang J., Guan H. Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia. Cerebellum. 2019;18:1137–1142. doi: 10.1007/s12311-019-01048-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-019-01048-y</ArticleId>
            <ArticleId IdType="pubmed">31179511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A., Shelly S., Zivelonghi C., Basal E., Dubey D., Flanagan E., Madhavan A.A., Mariotto S., Toledano M., Tracy J.A., et al.  Neuronal intermediate filament iggs in csf: Autoimmune axonopathy biomarkers. Ann. Clin. Transl. Neurol. 2021;8:425–439. doi: 10.1002/acn3.51284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.51284</ArticleId>
            <ArticleId IdType="pmc">PMC7886032</ArticleId>
            <ArticleId IdType="pubmed">33369283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L., Bataller L., Carpentier A.F., Aguirre-Cruz M.L., Saiz A., Benyahia B., Dalmau J., Graus F. Protein kinase cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J. Neurol. Neurosurg. Psychiatry. 2006;77:1359–1362. doi: 10.1136/jnnp.2006.097188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.097188</ArticleId>
            <ArticleId IdType="pmc">PMC2077410</ArticleId>
            <ArticleId IdType="pubmed">16801349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Kovacs G.G., Sabater L., Nagy P., Racz G., Miquel R., Dalmau J., Graus F. Protein kinase cγ antibodies and paraneoplastic cerebellar degeneration. J. Neuroimmunol. 2013;256:91–93. doi: 10.1016/j.jneuroim.2012.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2012.12.002</ArticleId>
            <ArticleId IdType="pubmed">23273977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat J.A., Lopez-Chiriboga A.S., Kryzer T.J., Fryer J.P., Devine M., Flores A., Lennon V.A., Pittock S.J., McKeon A. Autoimmune septin-5 cerebellar ataxia. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e474. doi: 10.1212/NXI.0000000000000474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000474</ArticleId>
            <ArticleId IdType="pmc">PMC6039209</ArticleId>
            <ArticleId IdType="pubmed">29998156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaguchi H., Yabe I., Takahashi H., Okumura F., Takeuchi A., Horiuchi K., Kano T., Kanda A., Saito W., Matsumoto M., et al.  Identification of anti-sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J. Neurol. 2014;261:224–226. doi: 10.1007/s00415-013-7134-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7134-5</ArticleId>
            <ArticleId IdType="pubmed">24272587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borsche M., Hahn S., Hanssen H., Münchau A., Wandinger K.-P., Brüggemann N. Sez6l2-antibody-associated progressive cerebellar ataxia: A differential diagnosis of atypical parkinsonism. J. Neurol. 2019;266:522–524. doi: 10.1007/s00415-018-9115-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-018-9115-1</ArticleId>
            <ArticleId IdType="pubmed">30460451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landa J., Guasp M., Petit-Pedrol M., Martínez-Hernández E., Planagumà J., Saiz A., Ruiz-García R., García-Fernández L., Verschuuren J., Saunders-Pullman R., et al.  Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:213–232. doi: 10.1212/NXI.0000000000000916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000916</ArticleId>
            <ArticleId IdType="pmc">PMC7641326</ArticleId>
            <ArticleId IdType="pubmed">33144342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Ringelstein M., Haas J., Serysheva I.I., Komorowski L., Fechner K., Wandinger K.-P., Albrecht P., Hefter H., Moser A., et al.  Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. J. Neuroinflamm. 2016;13:278. doi: 10.1186/s12974-016-0737-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0737-x</ArticleId>
            <ArticleId IdType="pmc">PMC5078930</ArticleId>
            <ArticleId IdType="pubmed">27776522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Scharf M., Begemann N., Stöcker W., Probst C., Serysheva I.I., Nagel S., Graus F., Psimaras D., Wildemann B., et al.  Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (itpr1) in cerebellar ataxia. J. Neuroinflamm. 2014;11:206. doi: 10.1186/s12974-014-0206-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-014-0206-3</ArticleId>
            <ArticleId IdType="pmc">PMC4300617</ArticleId>
            <ArticleId IdType="pubmed">25498830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berzero G., Hacohen Y., Komorowski L., Scharf M., Dehais C., Leclercq D., Fourchotte V., Buecher B., Honnorat J., Graus F., et al.  Paraneoplastic cerebellar degeneration associated with anti-itpr1 antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2017;4:e326. doi: 10.1212/NXI.0000000000000326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000326</ArticleId>
            <ArticleId IdType="pmc">PMC5292928</ArticleId>
            <ArticleId IdType="pubmed">28203616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfugham N., Gadoth A., Lennon V.A., Komorowski L., Scharf M., Hinson S., McKeon A., Pittock S.J.  Itpr1 Autoimmunity: Frequency, Neurologic Phenotype, and Cancer Association. Rehobot Atamiwoc; Addis Ababa, Ethiopia: 2018. 294p </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5778826</ArticleId>
            <ArticleId IdType="pubmed">29379822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Tan J., Sun H., Liu Y., Guan W., Jia J., Wang Z. Anti-sox1 antibodies in paraneoplastic neurological syndrome. J. Clin. Neurol. 2020;16:530–546. doi: 10.3988/jcn.2020.16.4.530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2020.16.4.530</ArticleId>
            <ArticleId IdType="pmc">PMC7541980</ArticleId>
            <ArticleId IdType="pubmed">33029958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Do D., Gupton S.L., Tanji K., Bastien J., Brugière S., Couté Y., Quadrio I., Rogemond V., Fabien N., Desestret V., et al.  Trim9 and trim67 are new targets in paraneoplastic cerebellar degeneration. Cerebellum. 2019;18:245–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6445697</ArticleId>
            <ArticleId IdType="pubmed">30350014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Coevorden-Hameete M.H., van Beuningen S.F.B., Perrenoud M., Will L.M., Hulsenboom E., Demonet J.-F., Sabater L., Kros J.M., Verschuuren J.J.G.M., Titulaer M.J., et al.  Antibodies to trim46 are associated with paraneoplastic neurological syndromes. Ann. Clin. Transl. Neurol. 2017;4:680–686. doi: 10.1002/acn3.396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.396</ArticleId>
            <ArticleId IdType="pmc">PMC5590547</ArticleId>
            <ArticleId IdType="pubmed">28904989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larman H.B., Zhao Z., Laserson U., Li M.Z., Ciccia A., Gakidis M.A.M., Church G.M., Kesari S., Leproust E.M., Solimini N.L., et al.  Autoantigen discovery with a synthetic human peptidome. Nat. Biotechnol. 2011;29:535–541. doi: 10.1038/nbt.1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1856</ArticleId>
            <ArticleId IdType="pmc">PMC4169279</ArticleId>
            <ArticleId IdType="pubmed">21602805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Etemadifar M., Aghababaei A., Nouri H., Kargaran P.K., Mohammadi S., Salari M. Autoimmune encephalitis: The first observational study from iran. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2021:1–10. doi: 10.1007/s10072-021-05400-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-021-05400-1</ArticleId>
            <ArticleId IdType="pubmed">34328580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyer S.G., Khakoo N.S., Aitcheson G., Perez C. Case of anti-zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. BMJ Case Rep. 2020;13:e235607. doi: 10.1136/bcr-2020-235607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2020-235607</ArticleId>
            <ArticleId IdType="pmc">PMC7500196</ArticleId>
            <ArticleId IdType="pubmed">32943444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gresa-Arribas N., Planaguma J., Petit-Pedrol M., Kawachi I., Katada S., Glaser C.A., Simabukuro M.M., Armangue T., Martinez-Hernandez E., Graus F., et al.  Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86:2235–2242. doi: 10.1212/WNL.0000000000002775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002775</ArticleId>
            <ArticleId IdType="pmc">PMC4909558</ArticleId>
            <ArticleId IdType="pubmed">27170573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loehrer P.A., Bien C.I., Dusoi A.E., Timmermann L., Simon O.J. Neurexin-3α-associated autoimmune encephalitis: A case report of full recovery after rituximab therapy. Eur. J. Neurol. 2020;27:e91–e93. doi: 10.1111/ene.14481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14481</ArticleId>
            <ArticleId IdType="pubmed">32803799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inui R., Saito K., Shimomura Y., Yamashita D., Kawamoto M., Ishikawa T. Anti-ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant hodgkin lymphoma: A case report. BMC Neurol. 2020;20:355.  doi: 10.1186/s12883-020-01929-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-020-01929-4</ArticleId>
            <ArticleId IdType="pmc">PMC7513504</ArticleId>
            <ArticleId IdType="pubmed">32967629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou Y., Xu S.-H., Zhang S.-R., Shu Q.-F., Liu X.-L. Anti-yo antibody-positive paraneoplastic cerebellar degeneration in a patient with possible cholangiocarcinoma: A case report and review of the literature. World J. Clin. Cases. 2021;9:4423–4432. doi: 10.12998/wjcc.v9.i17.4423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12998/wjcc.v9.i17.4423</ArticleId>
            <ArticleId IdType="pmc">PMC8173421</ArticleId>
            <ArticleId IdType="pubmed">34141810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudero D., Guasp M., Ariño H., Gaig C., Martínez-Hernández E., Dalmau J., Graus F. Antibody-associated cns syndromes without signs of inflammation in the elderly. Neurology. 2017;89:1471–1475. doi: 10.1212/WNL.0000000000004541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004541</ArticleId>
            <ArticleId IdType="pmc">PMC5631166</ArticleId>
            <ArticleId IdType="pubmed">28878050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A., Graus F., Dalmau J., Pifarré A., Marín C., Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 1999;46:774–777. doi: 10.1002/1531-8249(199911)46:5&lt;774::AID-ANA14&gt;3.0.CO;2-N.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;774::AID-ANA14&gt;3.0.CO;2-N</ArticleId>
            <ArticleId IdType="pubmed">10553996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mascalchi M., Vella A. Magnetic resonance and nuclear medicine imaging in ataxias. Handb. Clin. Neurol. 2012;103:85–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21827882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldarçara L., Currie S., Hadjivassiliou M., Hoggard N., Jack A., Jackowski A.P., Mascalchi M., Parazzini C., Reetz K., Righini A., et al.  Consensus paper: Radiological biomarkers of cerebellar diseases. Cerebellum. 2015;14:175–196. doi: 10.1007/s12311-014-0610-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-014-0610-3</ArticleId>
            <ArticleId IdType="pmc">PMC4929983</ArticleId>
            <ArticleId IdType="pubmed">25382714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhavan A.A., Carr C.M., Morris P.P., Flanagan E.P., Kotsenas A.L., Hunt C.H., Eckel L.J., Lindell E.P., Diehn F.E. Imaging review of paraneoplastic neurologic syndromes. AJNR. Am. J. Neuroradiol. 2020;41:2176–2187. doi: 10.3174/ajnr.A6815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A6815</ArticleId>
            <ArticleId IdType="pmc">PMC7963261</ArticleId>
            <ArticleId IdType="pubmed">33093137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahta A., Vijayvergia N., Bhavsar T.M., Ward L.D. Diagnostic approach to a patient with paraneoplastic neurological syndrome. World J. Oncol. 2012;3:243–246. doi: 10.4021/wjon571w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4021/wjon571w</ArticleId>
            <ArticleId IdType="pmc">PMC5649905</ArticleId>
            <ArticleId IdType="pubmed">29147315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilmore C.P., Elliott I., Auer D., Maddison P. Diffuse cerebellar mr imaging changes in anti-yo positive paraneoplastic cerebellar degeneration. J. Neurol. 2010;257:490–491. doi: 10.1007/s00415-009-5407-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5407-9</ArticleId>
            <ArticleId IdType="pubmed">19943166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y., Komatsu K., Nakagawa T., Matsumoto S. Transient diffusion-weighted imaging hyperintensity of the cerebellar cortex in paraneoplastic cerebellar degeneration. Intern. Med. 2019;58:619–620. doi: 10.2169/internalmedicine.1398-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.1398-18</ArticleId>
            <ArticleId IdType="pmc">PMC6421144</ArticleId>
            <ArticleId IdType="pubmed">30210124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karmon Y., Inbar E., Cordoba M., Gadoth N. Paraneoplastic cerebellar degeneration mimicking acute post-infectious cerebellitis. Cerebellum. 2009;8:441–444. doi: 10.1007/s12311-009-0128-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-009-0128-2</ArticleId>
            <ArticleId IdType="pubmed">19727999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K.-D., Kim J.S., Park S.-H., Kim Y.K., Kim S.E., Smitt P.S. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J. Neurol. Neurosurg. Psychiatry. 2006;77:525–528. doi: 10.1136/jnnp.2005.075325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2005.075325</ArticleId>
            <ArticleId IdType="pmc">PMC2077501</ArticleId>
            <ArticleId IdType="pubmed">16543536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroiss A., Uprimny C., Virgolini I.J. Thyroid carcinoma detected by incidental (18)f-fdg uptake in a patient with progressive cerebellar syndrome. Endocrine. 2016;51:199–200. doi: 10.1007/s12020-015-0646-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-015-0646-2</ArticleId>
            <ArticleId IdType="pubmed">26077948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Wang W., Zhao Y., Cui R. Cerebellar hypermetabolism in a case of paraneoplastic cerebellar syndrome with the primary lymphoepithelial carcinoma in tonsil. Clin. Nucl. Med. 2019;44:812–814. doi: 10.1097/RLU.0000000000002657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0000000000002657</ArticleId>
            <ArticleId IdType="pubmed">31162262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer M.J., Soffietti R., Dalmau J., Gilhus N.E., Giometto B., Graus F., Grisold W., Honnorat J., Sillevis Smitt P.A.E., Tanasescu R., et al.  Screening for tumours in paraneoplastic syndromes: Report of an efns task force. Eur. J. Neurol. 2011;18:19-e13. doi: 10.1111/j.1468-1331.2010.03220.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03220.x</ArticleId>
            <ArticleId IdType="pmc">PMC3086523</ArticleId>
            <ArticleId IdType="pubmed">20880069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper A.H., Samuels M.A., Klein P.J.  Adams and Victor’s Principles of Neurology. McGraw-Hill Medical; New York, NY, USA: 2019. </Citation>
        </Reference>
        <Reference>
          <Citation>Mitoma H., Hadjivassiliou M., Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14. doi: 10.1186/s40673-015-0034-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40673-015-0034-y</ArticleId>
            <ArticleId IdType="pmc">PMC4641375</ArticleId>
            <ArticleId IdType="pubmed">26561527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld M.R., Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin. Neurol. 2010;30:320–331. doi: 10.1055/s-0030-1255223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0030-1255223</ArticleId>
            <ArticleId IdType="pubmed">20577938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., Honig L.S., Benseler S.M., Kawachi I., Martinez-Hernandez E., et al.  Treatment and prognostic factors for long-term outcome in patients with anti-nmda receptor encephalitis: An observational cohort study. Lancet Neurol. 2013;12:157–165. doi: 10.1016/S1474-4422(12)70310-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70310-1</ArticleId>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czock D., Keller F., Rasche F.M., Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005;44:61–98. doi: 10.2165/00003088-200544010-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544010-00003</ArticleId>
            <ArticleId IdType="pubmed">15634032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt K.A., Sandoval K.E. Steroids and the blood-brain barrier: Therapeutic implications. Adv. Pharmacol. 2014;71:361–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25307223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T., Oishi T., Fukuoka Y., Nishikawa S., Iizuka N., Kato H. Potential effect of intravenous immunoglobulin against paraneoplastic cerebellar degeneration in progressive ovarian cancer. Gynecol. Oncol. Rep. 2020;34:100649. doi: 10.1016/j.gore.2020.100649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gore.2020.100649</ArticleId>
            <ArticleId IdType="pmc">PMC7509787</ArticleId>
            <ArticleId IdType="pubmed">33005721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu F.Q., Shang F.R., Liu J.J., Yuan H. Plasma exchange for treating anti-yo-associated paraneoplastic cerebellar degeneration: Case report and literature review. Medicine. 2020;99:e21760. doi: 10.1097/MD.0000000000021760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000021760</ArticleId>
            <ArticleId IdType="pmc">PMC7437810</ArticleId>
            <ArticleId IdType="pubmed">32872070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y., Tian X., Wang X., Xiao Z. Adverse effects of immunoglobulin therapy. Front. Immunol. 2018;9:1299. doi: 10.3389/fimmu.2018.01299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01299</ArticleId>
            <ArticleId IdType="pmc">PMC6008653</ArticleId>
            <ArticleId IdType="pubmed">29951056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flabeau O., Laurent C., Schneider S., Honnorat J., Ellie E. Spinal cord tractopathy in paraneoplastic anti-cv2/crmp5 myelitis responsive to plasma exchange. Rev. Neurol. 2021 doi: 10.1016/j.neurol.2021.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2021.04.009</ArticleId>
            <ArticleId IdType="pubmed">34247849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizenko C., Bennett J.L., Owens G., Vollmer T.L., Piquet A.L. A longitudinal, observational analysis of neuronal injury biomarkers in a case report of a patient with paraneoplastic anti-crmp5 antibody-associated transverse myelitis. Front. Neurol. 2021;12:691509. doi: 10.3389/fneur.2021.691509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.691509</ArticleId>
            <ArticleId IdType="pmc">PMC8328144</ArticleId>
            <ArticleId IdType="pubmed">34349723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chevret S., Hughes R.A., Annane D. Plasma exchange for guillain-barré syndrome. Cochrane Database Syst. Rev. 2017;2:Cd001798. doi: 10.1002/14651858.CD001798.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001798.pub3</ArticleId>
            <ArticleId IdType="pmc">PMC6464100</ArticleId>
            <ArticleId IdType="pubmed">28241090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rath J., Zulehner G., Schober B., Grisold A., Krenn M., Cetin H., Zimprich F. Real-world treatment of adult patients with guillain-barré syndrome over the last two decades. Sci. Rep. 2021;11:19170. doi: 10.1038/s41598-021-98501-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-98501-y</ArticleId>
            <ArticleId IdType="pmc">PMC8476500</ArticleId>
            <ArticleId IdType="pubmed">34580356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abboud H., Probasco J.C., Irani S., Ances B., Benavides D.R., Bradshaw M., Christo P.P., Dale R.C., Fernandez-Fournier M., Flanagan E.P., et al.  Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. J. Neurol. Neurosurg. Psychiatry. 2021;92:757–768. doi: 10.1136/jnnp-2020-325300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-325300</ArticleId>
            <ArticleId IdType="pmc">PMC8223680</ArticleId>
            <ArticleId IdType="pubmed">33649022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Grunewald R.A., Shanmugarajah P.D., Sarrigiannis P.G., Zis P., Skarlatou V., Hoggard N. Treatment of primary autoimmune cerebellar ataxia with mycophenolate. Cerebellum. 2020;19:680–684. doi: 10.1007/s12311-020-01152-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-020-01152-4</ArticleId>
            <ArticleId IdType="pmc">PMC7471147</ArticleId>
            <ArticleId IdType="pubmed">32524518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito M., Penza P., Orefice G., Pagano A., Parente E., Abbadessa A., Bonavita V. Successful treatment of paraneoplastic cerebellar degeneration with rituximab. J. Neuro-Oncol. 2008;86:363–364. doi: 10.1007/s11060-007-9479-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-007-9479-z</ArticleId>
            <ArticleId IdType="pubmed">17924058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poepel A., Jarius S., Heukamp L.C., Urbach H., Elger C.E., Bien C.G., Voltz R. Neurological course of long-term surviving patients with sclc and anti-hu syndrome. J. Neurol. Sci. 2007;263:145–148. doi: 10.1016/j.jns.2007.07.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2007.07.007</ArticleId>
            <ArticleId IdType="pubmed">17706677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294–305. doi: 10.1016/S1474-4422(02)00135-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(02)00135-7</ArticleId>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L., Graus F., Saiz A., Vilchez J.J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain J. Neurol. 2001;124:437–443. doi: 10.1093/brain/124.2.437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.2.437</ArticleId>
            <ArticleId IdType="pubmed">11157570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark E., Wurster U., Patzold U., Sailer M., Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch. Neurol. 1995;52:814–818. doi: 10.1001/archneur.1995.00540320098016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1995.00540320098016</ArticleId>
            <ArticleId IdType="pubmed">7639633</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34827413</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2076-3425</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain sciences</Title>
          <ISOAbbreviation>Brain Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Update on Paraneoplastic Cerebellar Degeneration.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1414</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci11111414</ELocationID>
        <Abstract>
          <AbstractText><b>Purpose of review:</b> To provide an update on paraneoplastic cerebellar degeneration (PCD), the involved antibodies and tumors, as well as management strategies. <b>Recent findings:</b> PCD represents the second most common presentation of the recently established class of immune mediated cerebellar ataxias (IMCAs). Although rare in general, PCD is one of the most frequent paraneoplastic presentations and characterized clinically by a rapidly progressive cerebellar syndrome. In recent years, several antibodies have been described in association with the clinical syndrome related to PCD; their clinical significance, however, has yet to be determined. The 2021 updated diagnostic criteria for paraneoplastic neurologic symptoms help to establish the diagnosis of PCD, direct cancer screening, and to evaluate the presence of these newly identified antibodies. Recognition of the clinical syndrome and prompt identification of a specific antibody are essential for early detection of an underlying malignancy and initiation of an appropriate treatment, which represents the best opportunity to modulate the course of the disease. As clinical symptoms can precede tumor diagnosis by years, co-occurrence of specific symptoms and antibodies should prompt continuous surveillance of the patient. <b>Summary:</b> We provide an in-depth overview on PCD, summarize recent findings related to PCD, and highlight the transformed diagnostic approach.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Loehrer</LastName>
            <ForeName>Philipp Alexander</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zieger</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simon</LastName>
            <ForeName>Ole J</ForeName>
            <Initials>OJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Gießen and Marburg, 35043 Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain Sci</MedlineTA>
        <NlmUniqueID>101598646</NlmUniqueID>
        <ISSNLinking>2076-3425</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Tr/DNER-antibody</Keyword>
        <Keyword MajorTopicYN="N">Yo-antibody</Keyword>
        <Keyword MajorTopicYN="N">immune-mediated cerebellar ataxias</Keyword>
        <Keyword MajorTopicYN="N">mGluR1-antibody</Keyword>
        <Keyword MajorTopicYN="N">onconeuronal antibodies</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic syndromes</Keyword>
      </KeywordList>
      <CoiStatement>We declare that none of the authors have competing financial or non-financial interests related to this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34827413</ArticleId>
        <ArticleId IdType="pmc">PMC8615604</ArticleId>
        <ArticleId IdType="doi">10.3390/brainsci11111414</ArticleId>
        <ArticleId IdType="pii">brainsci11111414</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mitoma H., Manto M., Hadjivassiliou M. Immune-mediated cerebellar ataxias: Clinical diagnosis and treatment based on immunological and physiological mechanisms. J. Mov. Disord. 2021;14:10–28. doi: 10.14802/jmd.20040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14802/jmd.20040</ArticleId>
            <ArticleId IdType="pmc">PMC7840241</ArticleId>
            <ArticleId IdType="pubmed">33423437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Martindale J., Shanmugarajah P., Grünewald R.A., Sarrigiannis P.G., Beauchamp N., Garrard K., Warburton R., Sanders D.S., Friend D., et al.  Causes of progressive cerebellar ataxia: Prospective evaluation of 1500 patients. J. Neurol. Neurosurg. Psychiatry. 2017;88:301–309. doi: 10.1136/jnnp-2016-314863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-314863</ArticleId>
            <ArticleId IdType="pubmed">27965395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A., Gigli G.L., Segatti S., Corazza E., Marini A., Bernardini A., Valent F., Fabris M., Curcio F., Brigo F., et al.  Epidemiology of paraneoplastic neurological syndromes: A population-based study. J. Neurol. 2020;267:26–35. doi: 10.1007/s00415-019-09544-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09544-1</ArticleId>
            <ArticleId IdType="pubmed">31552550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brouwer V. Beitrag zur kenntnis der chronishen diffusen kleinhirnerkrankungen. Neurol. Cbl. 1919;38:674–682.</Citation>
        </Reference>
        <Reference>
          <Citation>Greenlee J.E., Brashear H.R. Antibodies to cerebellar purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann. Neurol. 1983;14:609–613. doi: 10.1002/ana.410140603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410140603</ArticleId>
            <ArticleId IdType="pubmed">6360029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Vogrig A., Muñiz-Castrillo S., Antoine J.-C.G., Desestret V., Dubey D., Giometto B., Irani S.R., Joubert B., Leypoldt F., et al.  Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:e1014. doi: 10.1212/NXI.0000000000001014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000001014</ArticleId>
            <ArticleId IdType="pmc">PMC8237398</ArticleId>
            <ArticleId IdType="pubmed">34006622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loehrer P.A., Timmermann L., Pehl A., Bien C.I., Pfestroff A., Pedrosa D.J. Rhombencephalitis associated with isolated zic4-antibodies in paraneoplastic cerebellar degeneration: A case report. BMC Neurol. 2020;20:208.  doi: 10.1186/s12883-020-01788-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-020-01788-z</ArticleId>
            <ArticleId IdType="pmc">PMC7249364</ArticleId>
            <ArticleId IdType="pubmed">32450842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Rosenfeld M.R., Dalmau J. Update on neurological paraneoplastic syndromes. Curr. Opin. Oncol. 2015;27:489–495. doi: 10.1097/CCO.0000000000000222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000222</ArticleId>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pignolet B.S., Gebauer C.M., Liblau R.S. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology. 2013;2:e27384. doi: 10.4161/onci.27384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/onci.27384</ArticleId>
            <ArticleId IdType="pmc">PMC3913668</ArticleId>
            <ArticleId IdType="pubmed">24501693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Qian W., Chen Q., Yin L., Li B., Wang H. Imbalance in circulating t lymphocyte subsets contributes to hu antibody-associated paraneoplastic neurological syndromes. Cell. Immunol. 2014;290:245–250. doi: 10.1016/j.cellimm.2014.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2014.06.009</ArticleId>
            <ArticleId IdType="pubmed">25173445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., Vincent A. P/q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002;59:764–766. doi: 10.1212/WNL.59.5.764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.59.5.764</ArticleId>
            <ArticleId IdType="pubmed">12221175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A., Lang B., Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the lambert-eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989;12:496–502. doi: 10.1016/0166-2236(89)90109-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(89)90109-4</ArticleId>
            <ArticleId IdType="pubmed">2480664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coesmans M., Smitt P.A., Linden D.J., Shigemoto R., Hirano T., Yamakawa Y., van Alphen A.M., Luo C., van der Geest J.N., Kros J.M., et al.  Mechanisms underlying cerebellar motor deficits due to mglur1-autoantibodies. Ann. Neurol. 2003;53:325–336. doi: 10.1002/ana.10451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10451</ArticleId>
            <ArticleId IdType="pubmed">12601700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y.J., Safa P., Chen Y.R., Sobel R.A., Boyden E.S., Tsien R.W. Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc. Natl. Acad. Sci. USA. 2008;105:2705–2710. doi: 10.1073/pnas.0710771105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0710771105</ArticleId>
            <ArticleId IdType="pmc">PMC2268200</ArticleId>
            <ArticleId IdType="pubmed">18272482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson K., Rosenblum M.K., Kotanides H., Posner J.B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-yo antibody-positive patients. Neurology. 1992;42:1931–1937. doi: 10.1212/01.wnl.0000407657.51588.5a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000407657.51588.5a</ArticleId>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I., Graus F., Keime-Guibert F., Reñé R., Delattre J.Y., Ramón J.M., Dalmau J., Posner J.B. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-yo antibodies. Neurology. 2000;55:713–715. doi: 10.1212/WNL.55.5.713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams’ili S., Grefkens J., de Leeuw B., van den Bent M., Hooijkaas H., van der Holt B., Vecht C., Sillevis Smitt P. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain J. Neurol. 2003;126:1409–1418. doi: 10.1093/brain/awg133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Rosenfeld M.R. Paraneoplastic syndromes of the cns. Lancet Neurol. 2008;7:327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grativvol R.S., Cavalcante W.C.P., Castro L.H.M., Nitrini R., Simabukuro M.M. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr. Oncol. Rep. 2018;20:92. doi: 10.1007/s11912-018-0721-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-018-0721-y</ArticleId>
            <ArticleId IdType="pubmed">30415318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitoma H., Adhikari K., Aeschlimann D., Chattopadhyay P., Hadjivassiliou M., Hampe C.S., Honnorat J., Joubert B., Kakei S., Lee J., et al.  Consensus paper: Neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:213–232. doi: 10.1007/s12311-015-0664-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-015-0664-x</ArticleId>
            <ArticleId IdType="pmc">PMC4591117</ArticleId>
            <ArticleId IdType="pubmed">25823827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducray F., Demarquay G., Graus F., Decullier E., Antoine J.C., Giometto B., Psimaras D., Delattre J.Y., Carpentier A.F., Honnorat J. Seronegative paraneoplastic cerebellar degeneration: The pns euronetwork experience. Eur. J. Neurol. 2014;21:731–735. doi: 10.1111/ene.12368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12368</ArticleId>
            <ArticleId IdType="pubmed">24471811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sechi E., Flanagan E.P. Antibody-mediated autoimmune diseases of the cns: Challenges and approaches to diagnosis and management. Front. Neurol. 2021;12:673339. doi: 10.3389/fneur.2021.673339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.673339</ArticleId>
            <ArticleId IdType="pmc">PMC8292678</ArticleId>
            <ArticleId IdType="pubmed">34305787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillevis Smitt P.A., Manley G.T., Posner J.B. Immunization with the paraneoplastic encephalomyelitis antigen hud does not cause neurologic disease in mice. Neurology. 1995;45:1873–1878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7477985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka K., Tanaka M., Igarashi S., Onodera O., Miyatake T., Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin. Neurol. Neurosurg. 1995;97:101–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7788964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpentier A.F., Rosenfeld M.R., Delattre J.Y., Whalen R.G., Posner J.B., Dalmau J. DNA vaccination with hud inhibits growth of a neuroblastoma in mice. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 1998;4:2819–2824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9829748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E., Dalmau J. Neuronal autoantigens—Pathogenesis, associated disorders and antibody testing. Nat. Rev. Neurol. 2012;8:380–390. doi: 10.1038/nrneurol.2012.99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2012.99</ArticleId>
            <ArticleId IdType="pmc">PMC3718498</ArticleId>
            <ArticleId IdType="pubmed">22710628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okano H.J., Park W.Y., Corradi J.P., Darnell R.B. The cytoplasmic purkinje onconeural antigen cdr2 down-regulates c-myc function: Implications for neuronal and tumor cell survival. Genes Dev. 1999;13:2087–2097. doi: 10.1101/gad.13.16.2087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.13.16.2087</ArticleId>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K., Kitagawa Y., Saiki S., Saiki M., Hirose G. Effect of a paraneoplastic cerebellar degeneration-associated neural protein on b-myb promoter activity. Neurobiol. Dis. 2004;15:529–533. doi: 10.1016/j.nbd.2003.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2003.11.003</ArticleId>
            <ArticleId IdType="pubmed">15056460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert M.L., Austin L.M., Darnell R.B. Detection and treatment of activated t cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 2000;47:9–17. doi: 10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I</ArticleId>
            <ArticleId IdType="pubmed">10632096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rousseau A., Benyahia B., Dalmau J., Connan F., Guillet J.G., Delattre J.Y., Choppin J. T cell response to hu-d peptides in patients with anti-hu syndrome. J. Neuro-Oncol. 2005;71:231–236. doi: 10.1007/s11060-004-1723-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-004-1723-1</ArticleId>
            <ArticleId IdType="pmc">PMC2586925</ArticleId>
            <ArticleId IdType="pubmed">15735910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aye M.M., Kasai T., Tashiro Y., Xing H.Q., Shirahama H., Mitsuda M., Suetsugu T., Tanaka K., Osame M., Izumo S. Cd8 positive t-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J. Neuroimmunol. 2009;208:136–140. doi: 10.1016/j.jneuroim.2009.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.01.017</ArticleId>
            <ArticleId IdType="pubmed">19217169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plonquet A., Gherardi R.K., Créange A., Antoine J.C., Benyahia B., Grisold W., Drlicek M., Dreyfus P., Honnorat J., Khouatra C., et al.  Oligoclonal t-cells in blood and target tissues of patients with anti-hu syndrome. J. Neuroimmunol. 2002;122:100–105. doi: 10.1016/S0165-5728(01)00452-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(01)00452-0</ArticleId>
            <ArticleId IdType="pubmed">11777548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R., Dalmau J., Posner J.B., Rosenfeld M.R. T-cell receptor analysis in anti-hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51:1146–1150. doi: 10.1212/WNL.51.4.1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.51.4.1146</ArticleId>
            <ArticleId IdType="pubmed">9781545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda T., Motomura M., Nakao Y., Shiraishi H., Yoshimura T., Iwanaga K., Tsujihata M., Eguchi K. Reduction of p/q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with lambert-eaton myasthenic syndrome. Ann. Neurol. 2003;53:21–28. doi: 10.1002/ana.10392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10392</ArticleId>
            <ArticleId IdType="pubmed">12509844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hildebrand M.E., Isope P., Miyazaki T., Nakaya T., Garcia E., Feltz A., Schneider T., Hescheler J., Kano M., Sakimura K., et al.  Functional coupling between mglur1 and cav3.1 t-type calcium channels contributes to parallel fiber-induced fast calcium signaling within purkinje cell dendritic spines. J. Neurosci. Off. J. Soc. Neurosci. 2009;29:9668–9682. doi: 10.1523/JNEUROSCI.0362-09.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0362-09.2009</ArticleId>
            <ArticleId IdType="pmc">PMC6666586</ArticleId>
            <ArticleId IdType="pubmed">19657020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hébert J., Riche B., Vogrig A., Muñiz-Castrillo S., Joubert B., Picard G., Rogemond V., Psimaras D., Alentorn A., Berzero G., et al.  Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in france. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e883. doi: 10.1212/NXI.0000000000000883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000883</ArticleId>
            <ArticleId IdType="pmc">PMC7455315</ArticleId>
            <ArticleId IdType="pubmed">32847939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.S., Kwon S., Ki C.S., Youn J., Cho J.W. The etiologies of chronic progressive cerebellar ataxia in a korean population. J. Clin. Neurol. 2018;14:374–380. doi: 10.3988/jcn.2018.14.3.374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2018.14.3.374</ArticleId>
            <ArticleId IdType="pmc">PMC6032000</ArticleId>
            <ArticleId IdType="pubmed">29971977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebus O., Montaut S., Monga B., Wirth T., Cheraud C., Alves Do Rego C., Zinchenko I., Carré G., Hamdaoui M., Hautecloque G., et al.  Deciphering the causes of sporadic late-onset cerebellar ataxias: A prospective study with implications for diagnostic work. J. Neurol. 2017;264:1118–1126. doi: 10.1007/s00415-017-8500-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-017-8500-5</ArticleId>
            <ArticleId IdType="pubmed">28478596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaff E., Maat P., Hulsenboom E., van den Berg R., van den Bent M., Demmers J., Lugtenburg P.J., Hoogenraad C.C., Sillevis Smitt P. Identification of delta/notch-like epidermal growth factor-related receptor as the tr antigen in paraneoplastic cerebellar degeneration. Ann. Neurol. 2012;71:815–824. doi: 10.1002/ana.23550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23550</ArticleId>
            <ArticleId IdType="pubmed">22447725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A., Tracy J.A., Pittock S.J., Parisi J.E., Klein C.J., Lennon V.A. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: The cerebellum and beyond. Arch. Neurol. 2011;68:1282–1289. doi: 10.1001/archneurol.2011.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.128</ArticleId>
            <ArticleId IdType="pubmed">21670387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Graus F., Rosenblum M.K., Posner J.B. Anti-hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine. 1992;71:59–72. doi: 10.1097/00005792-199203000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-199203000-00001</ArticleId>
            <ArticleId IdType="pubmed">1312211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann. Neurol. 2003;53:580–587. doi: 10.1002/ana.10518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10518</ArticleId>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bürk K., Wick M., Roth G., Decker P., Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J. Neurol. 2010;257:59–62. doi: 10.1007/s00415-009-5262-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5262-8</ArticleId>
            <ArticleId IdType="pubmed">19629562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L., Höftberger R., Boronat A., Saiz A., Dalmau J., Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS ONE. 2013;8:e60438.  doi: 10.1371/journal.pone.0060438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0060438</ArticleId>
            <ArticleId IdType="pmc">PMC3607586</ArticleId>
            <ArticleId IdType="pubmed">23536908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler C., Verschuuren J.J., et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Lennon V.A., Gadoth A., Pittock S.J., Flanagan E.P., Schmeling J.E., McKeon A., Klein C.J. Autoimmune crmp5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90:e103–e110. doi: 10.1212/WNL.0000000000004803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004803</ArticleId>
            <ArticleId IdType="pubmed">29222126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J., Cartalat-Carel S., Ricard D., Camdessanche J.P., Carpentier A.F., Rogemond V., Chapuis F., Aguera M., Decullier E., Duchemin A.M., et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with hu or cv2/crmp5 antibodies. J. Neurol. Neurosurg. Psychiatry. 2009;80:412–416. doi: 10.1136/jnnp.2007.138016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.138016</ArticleId>
            <ArticleId IdType="pmc">PMC2664637</ArticleId>
            <ArticleId IdType="pubmed">18931014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Z., Kryzer T.J., Griesmann G.E., Kim K., Benarroch E.E., Lennon V.A. Crmp-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity. Ann. Neurol. 2001;49:146–154. doi: 10.1002/1531-8249(20010201)49:2&lt;146::AID-ANA34&gt;3.0.CO;2-E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;146::AID-ANA34&gt;3.0.CO;2-E</ArticleId>
            <ArticleId IdType="pubmed">11220734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F., Keime-Guibert F., Rene R., Benyahia B., Ribalta T., Ascaso C., Escaramis G., Delattre J.Y. Anti-hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain J. Neurol. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J., Graus F., Villarejo A., Posner J.B., Blumenthal D., Thiessen B., Saiz A., Meneses P., Rosenfeld M.R. Clinical analysis of anti-ma2-associated encephalitis. Brain J. Neurol. 2004;127:1831–1844. doi: 10.1093/brain/awh203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh203</ArticleId>
            <ArticleId IdType="pubmed">15215214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann L.A., Jarius S., Pellkofer H.L., Schueller M., Krumbholz M., Koenig F., Johannis W., la Fougere C., Newman T., Vincent A., et al.  Anti-ma and anti-ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J. Neurol. Neurosurg. Psychiatry. 2008;79:767–773. doi: 10.1136/jnnp.2007.118588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.118588</ArticleId>
            <ArticleId IdType="pubmed">18223018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simard C., Vogrig A., Joubert B., Muñiz-Castrillo S., Picard G., Rogemond V., Ducray F., Berzero G., Psimaras D., Antoine J.C., et al.  Clinical spectrum and diagnostic pitfalls of neurologic syndromes with ri antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e699. doi: 10.1212/NXI.0000000000000699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000699</ArticleId>
            <ArticleId IdType="pmc">PMC7136048</ArticleId>
            <ArticleId IdType="pubmed">32170042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernal F., Shams’ili S., Rojas I., Sanchez-Valle R., Saiz A., Dalmau J., Honnorat J., Sillevis Smitt P., Graus F. Anti-tr antibodies as markers of paraneoplastic cerebellar degeneration and hodgkin’s disease. Neurology. 2003;60:230–234. doi: 10.1212/01.WNL.0000041495.87539.98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000041495.87539.98</ArticleId>
            <ArticleId IdType="pubmed">12552036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Jitprapaikulsan J., Bi H., Do Campo R.V., McKeon A., Pittock S.J., Engelstad J.K., Mills J.R., Klein C.J. Amphiphysin-igg autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93:e1873–e1880. doi: 10.1212/WNL.0000000000008472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008472</ArticleId>
            <ArticleId IdType="pubmed">31624089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Parisi J.E., Benarroch E.E., Mokri B., Stephan C.L., Kim K.K., Kilimann M.W., Lennon V.A. Amphiphysin autoimmunity: Paraneoplastic accompaniments. Ann. Neurol. 2005;58:96–107. doi: 10.1002/ana.20529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20529</ArticleId>
            <ArticleId IdType="pubmed">15984030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Hinson S.R., Jolliffe E.A., Zekeridou A., Flanagan E.P., Pittock S.J., Basal E., Drubach D.A., Lachance D.H., Lennon V.A., et al.  Autoimmune gfap astrocytopathy: Prospective evaluation of 90 patients in 1 year. J. Neuroimmunol. 2018;321:157–163. doi: 10.1016/j.jneuroim.2018.04.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2018.04.016</ArticleId>
            <ArticleId IdType="pubmed">29793728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A., Blanco Y., Sabater L., González F., Bataller L., Casamitjana R., Ramió-Torrentà L., Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: Diagnostic clues for this association. Brain J. Neurol. 2008;131:2553–2563. doi: 10.1093/brain/awn183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn183</ArticleId>
            <ArticleId IdType="pubmed">18687732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandel-Brehm C., Dubey D., Kryzer T.J., O’Donovan B.D., Tran B., Vazquez S.E., Sample H.A., Zorn K.C., Khan L.M., Bledsoe I.O., et al.  Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N. Engl. J. Med. 2019;381:47–54. doi: 10.1056/NEJMoa1816721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1816721</ArticleId>
            <ArticleId IdType="pmc">PMC6800027</ArticleId>
            <ArticleId IdType="pubmed">31269365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maudes E., Landa J., Muñoz-Lopetegi A., Armangue T., Alba M., Saiz A., Graus F., Dalmau J., Sabater L. Clinical significance of kelch-like protein 11 antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e666. doi: 10.1212/NXI.0000000000000666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000666</ArticleId>
            <ArticleId IdType="pmc">PMC7051195</ArticleId>
            <ArticleId IdType="pubmed">31953318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey D., Wilson M.R., Clarkson B., Giannini C., Gandhi M., Cheville J., Lennon V.A., Eggers S., Devine M.F., Mandel-Brehm C., et al.  Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol. 2020;77:1420–1429. doi: 10.1001/jamaneurol.2020.2231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.2231</ArticleId>
            <ArticleId IdType="pmc">PMC7653501</ArticleId>
            <ArticleId IdType="pubmed">32744608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zis P., Rao D.G., Hoggard N., Sarrigiannis P.G., Hadjivassiliou M. Anti-mag associated cerebellar ataxia and response to rituximab. J. Neurol. 2018;265:115–118. doi: 10.1007/s00415-017-8675-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-017-8675-9</ArticleId>
            <ArticleId IdType="pubmed">29159464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S., Lennon V.A. New purkinje cell antibody (pca-2): Marker of lung cancer-related neurological autoimmunity. Ann. Neurol. 2000;47:297–305. doi: 10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4</ArticleId>
            <ArticleId IdType="pubmed">10716248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadoth A., Kryzer T.J., Fryer J., McKeon A., Lennon V.A., Pittock S.J. Microtubule-associated protein 1b: Novel paraneoplastic biomarker. Ann. Neurol. 2017;81:266–277. doi: 10.1002/ana.24872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24872</ArticleId>
            <ArticleId IdType="pubmed">28074593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani S.R., Pettingill P., Kleopa K.A., Schiza N., Waters P., Mazia C., Zuliani L., Watanabe O., Lang B., Buckley C., et al.  Morvan syndrome: Clinical and serological observations in 29 cases. Ann. Neurol. 2012;72:241–255. doi: 10.1002/ana.23577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23577</ArticleId>
            <ArticleId IdType="pubmed">22473710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñiz-Castrillo S., Joubert B., Elsensohn M.H., Pinto A.L., Saint-Martin M., Vogrig A., Picard G., Rogemond V., Dubois V., Tamouza R., et al.  Anti-caspr2 clinical phenotypes correlate with hla and immunological features. J. Neurol. Neurosurg. Psychiatry. 2020;91:1076–1084. doi: 10.1136/jnnp-2020-323226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-323226</ArticleId>
            <ArticleId IdType="pubmed">32651251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joubert B., Saint-Martin M., Noraz N., Picard G., Rogemond V., Ducray F., Desestret V., Psimaras D., Delattre J.Y., Antoine J.C., et al.  Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 2016;73:1115–1124. doi: 10.1001/jamaneurol.2016.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.1585</ArticleId>
            <ArticleId IdType="pubmed">27428927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin W.O., Lennon V.A., Komorowski L., Probst C., Clardy S.L., Aksamit A.J., Appendino J.P., Lucchinetti C.F., Matsumoto J.Y., Pittock S.J., et al.  Dppx potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–1803. doi: 10.1212/WNL.0000000000000991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000991</ArticleId>
            <ArticleId IdType="pmc">PMC4240433</ArticleId>
            <ArticleId IdType="pubmed">25320100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara M., Ariño H., Petit-Pedrol M., Sabater L., Titulaer M.J., Martinez-Hernandez E., Schreurs M.W., Rosenfeld M.R., Graus F., Dalmau J. Dppx antibody-associated encephalitis: Main syndrome and antibody effects. Neurology. 2017;88:1340–1348. doi: 10.1212/WNL.0000000000003796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003796</ArticleId>
            <ArticleId IdType="pmc">PMC5379928</ArticleId>
            <ArticleId IdType="pubmed">28258082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., Peles E., Buckley C., Lang B., Vincent A. Antibodies to kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, morvan’s syndrome and acquired neuromyotonia. Brain J. Neurol. 2010;133:2734–2748. doi: 10.1093/brain/awq213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awq213</ArticleId>
            <ArticleId IdType="pmc">PMC2929337</ArticleId>
            <ArticleId IdType="pubmed">20663977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadoth A., Pittock S.J., Dubey D., McKeon A., Britton J.W., Schmeling J.E., Smith A., Kotsenas A.L., Watson R.E., Lachance D.H., et al.  Expanded phenotypes and outcomes among 256 lgi1/caspr2-igg-positive patients. Ann. Neurol. 2017;82:79–92. doi: 10.1002/ana.24979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24979</ArticleId>
            <ArticleId IdType="pubmed">28628235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Chiriboga A.S., Komorowski L., Kümpfel T., Probst C., Hinson S.R., Pittock S.J., McKeon A. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. Neurology. 2016;86:1009–1013. doi: 10.1212/WNL.0000000000002476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002476</ArticleId>
            <ArticleId IdType="pmc">PMC4799712</ArticleId>
            <ArticleId IdType="pubmed">26888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zalewski N.L., Lennon V.A., Lachance D.H., Klein C.J., Pittock S.J., McKeon A. P/q- and n-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54:220–227. doi: 10.1002/mus.25027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25027</ArticleId>
            <ArticleId IdType="pmc">PMC4940238</ArticleId>
            <ArticleId IdType="pubmed">26789908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Graus F., Honnorat J., Jarius S., Titulaer M., Manto M., Hoggard N., Sarrigiannis P., Mitoma H. Diagnostic criteria for primary autoimmune cerebellar ataxia-guidelines from an international task force on immune-mediated cerebellar ataxias. Cerebellum. 2020;19:605–610. doi: 10.1007/s12311-020-01132-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-020-01132-8</ArticleId>
            <ArticleId IdType="pmc">PMC7351847</ArticleId>
            <ArticleId IdType="pubmed">32328884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-pkc-gamma, anti-glur-delta2, anti-ca/arhgap26 and anti-vgcc. J. Neuroinflamm. 2015;12:167. doi: 10.1186/s12974-015-0357-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0357-x</ArticleId>
            <ArticleId IdType="pmc">PMC4574118</ArticleId>
            <ArticleId IdType="pubmed">26377184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Alfugham N., O’Connor K., Hinson S., Kunchok A., Lennon V.A., Komorowski L., Probst C., McKeon A. Gtpase regulator associated with focal adhesion kinase 1 (graf1) immunoglobulin-associated ataxia and neuropathy. Mov. Disord. Clin. Pract. 2020;7:904–909. doi: 10.1002/mdc3.13036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mdc3.13036</ArticleId>
            <ArticleId IdType="pmc">PMC7604666</ArticleId>
            <ArticleId IdType="pubmed">33163561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L., Sabater L., Saiz A., Serra C., Claramonte B., Graus F. Carbonic anhydrase-related protein viii: Autoantigen in paraneoplastic cerebellar degeneration. Ann. Neurol. 2004;56:575–579. doi: 10.1002/ana.20238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20238</ArticleId>
            <ArticleId IdType="pubmed">15389893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Sabater L., Velasco F., Ciordia R., Dalmau J., Graus F. Carbonic anhydrase-related protein viii antibodies and paraneoplastic cerebellar degeneration. Neuropathol. Appl. Neurobiol. 2014;40:650–653. doi: 10.1111/nan.12118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12118</ArticleId>
            <ArticleId IdType="pmc">PMC4077932</ArticleId>
            <ArticleId IdType="pubmed">24446689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prevezianou A., Tzartos J.S., Dagklis I.E., Bentenidi E., Angelopoulos P., Bostantjopoulou S. Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein viii autoantibodies. J. Neuroimmunol. 2020;344:577242. doi: 10.1016/j.jneuroim.2020.577242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2020.577242</ArticleId>
            <ArticleId IdType="pubmed">32325285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swayne A., Tjoa L., Broadley S., Dionisio S., Gillis D., Jacobson L., Woodhall M.R., McNabb A., Schweitzer D., Tsang B., et al.  Antiglycine receptor antibody related disease: A case series and literature review. Eur. J. Neurol. 2018;25:1290–1298. doi: 10.1111/ene.13721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13721</ArticleId>
            <ArticleId IdType="pmc">PMC6282944</ArticleId>
            <ArticleId IdType="pubmed">29904974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa-head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mglur1, anti-homer-3, anti-sj/itpr1 and anti-carp viii. J. Neuroinflamm. 2015;12:166. doi: 10.1186/s12974-015-0356-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0356-y</ArticleId>
            <ArticleId IdType="pmc">PMC4574226</ArticleId>
            <ArticleId IdType="pubmed">26377085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Ren H., Li L., Wang J., Fechner K., Guan H. Anti-homer-3 antibody associated cerebellar ataxia: A rare case report and literature review. J. Neuroimmunol. 2019;330:155–158. doi: 10.1016/j.jneuroim.2019.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2019.01.002</ArticleId>
            <ArticleId IdType="pubmed">30904736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuliani L., Sabater L., Saiz A., Baiges J.J., Giometto B., Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. 2007;68:239–240. doi: 10.1212/01.wnl.0000251308.79366.f9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000251308.79366.f9</ArticleId>
            <ArticleId IdType="pubmed">17224583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Sabater L., Ortega A., Dalmau J., Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol. 2013;70:506–509. doi: 10.1001/jamaneurol.2013.1955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.1955</ArticleId>
            <ArticleId IdType="pmc">PMC3723144</ArticleId>
            <ArticleId IdType="pubmed">23400636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-García R., Martínez-Hernández E., Joubert B., Petit-Pedrol M., Pajarón-Boix E., Fernández V., Salais L., Del Pozo M., Armangué T., Sabater L., et al.  Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e658. doi: 10.1212/NXI.0000000000000658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000658</ArticleId>
            <ArticleId IdType="pmc">PMC6943365</ArticleId>
            <ArticleId IdType="pubmed">31826987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mange L., Haitao R., Lixin Z., Siyuan F., Jing W., Hongzhi G. Cerebellar ataxia and myeloradiculopathy associated with ap3b2 antibody: A case report and literature review. J. Neurol. 2021;268:4163–4169. doi: 10.1007/s00415-021-10496-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-021-10496-8</ArticleId>
            <ArticleId IdType="pubmed">33988764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell R.B., Furneaux H.M., Posner J.B. Antiserum from a patient with cerebellar degeneration identifies a novel protein in purkinje cells, cortical neurons, and neuroectodermal tumors. J. Neurosci. Off. J. Soc. Neurosci. 1991;11:1224–1230. doi: 10.1523/JNEUROSCI.11-05-01224.1991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.11-05-01224.1991</ArticleId>
            <ArticleId IdType="pmc">PMC6575333</ArticleId>
            <ArticleId IdType="pubmed">1851215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Wildemann B. ‘Medusa head ataxia’: The expanding spectrum of purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-yo/cdr2, anti-nb/ap3b2, pca-2, anti-tr/dner, other antibodies, diagnostic pitfalls, summary and outlook. J. Neuroinflamm. 2015;12:168. doi: 10.1186/s12974-015-0358-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
            <ArticleId IdType="pmc">PMC4573944</ArticleId>
            <ArticleId IdType="pubmed">26377319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miske R., Gross C.C., Scharf M., Golombeck K.S., Hartwig M., Bhatia U., Schulte-Mecklenbeck A., Bönte K., Strippel C., Schöls L., et al.  Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol. Neuroimmunol. Neuroinflamm. 2017;4:e307. doi: 10.1212/NXI.0000000000000307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000307</ArticleId>
            <ArticleId IdType="pmc">PMC5141526</ArticleId>
            <ArticleId IdType="pubmed">27957508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S., Kryzer T.J., Komorowski L., Miske R., Anderson M.D., Flanagan E.P., Hinson S.R., Lennon V.A., Pittock S.J., McKeon A. Neurochondrin neurological autoimmunity. Neurol. Neuroimmunol. Neuroinflamm. 2019;6:e612. doi: 10.1212/NXI.0000000000000612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
            <ArticleId IdType="pmc">PMC6745726</ArticleId>
            <ArticleId IdType="pubmed">31511329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Ren H., Fang F., Yang X., Wang J., Guan H. Neurochondrin antibody serum positivity in three cases of autoimmune cerebellar ataxia. Cerebellum. 2019;18:1137–1142. doi: 10.1007/s12311-019-01048-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-019-01048-y</ArticleId>
            <ArticleId IdType="pubmed">31179511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A., Shelly S., Zivelonghi C., Basal E., Dubey D., Flanagan E., Madhavan A.A., Mariotto S., Toledano M., Tracy J.A., et al.  Neuronal intermediate filament iggs in csf: Autoimmune axonopathy biomarkers. Ann. Clin. Transl. Neurol. 2021;8:425–439. doi: 10.1002/acn3.51284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.51284</ArticleId>
            <ArticleId IdType="pmc">PMC7886032</ArticleId>
            <ArticleId IdType="pubmed">33369283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L., Bataller L., Carpentier A.F., Aguirre-Cruz M.L., Saiz A., Benyahia B., Dalmau J., Graus F. Protein kinase cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J. Neurol. Neurosurg. Psychiatry. 2006;77:1359–1362. doi: 10.1136/jnnp.2006.097188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.097188</ArticleId>
            <ArticleId IdType="pmc">PMC2077410</ArticleId>
            <ArticleId IdType="pubmed">16801349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R., Kovacs G.G., Sabater L., Nagy P., Racz G., Miquel R., Dalmau J., Graus F. Protein kinase cγ antibodies and paraneoplastic cerebellar degeneration. J. Neuroimmunol. 2013;256:91–93. doi: 10.1016/j.jneuroim.2012.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2012.12.002</ArticleId>
            <ArticleId IdType="pubmed">23273977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat J.A., Lopez-Chiriboga A.S., Kryzer T.J., Fryer J.P., Devine M., Flores A., Lennon V.A., Pittock S.J., McKeon A. Autoimmune septin-5 cerebellar ataxia. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e474. doi: 10.1212/NXI.0000000000000474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000474</ArticleId>
            <ArticleId IdType="pmc">PMC6039209</ArticleId>
            <ArticleId IdType="pubmed">29998156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaguchi H., Yabe I., Takahashi H., Okumura F., Takeuchi A., Horiuchi K., Kano T., Kanda A., Saito W., Matsumoto M., et al.  Identification of anti-sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. J. Neurol. 2014;261:224–226. doi: 10.1007/s00415-013-7134-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7134-5</ArticleId>
            <ArticleId IdType="pubmed">24272587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borsche M., Hahn S., Hanssen H., Münchau A., Wandinger K.-P., Brüggemann N. Sez6l2-antibody-associated progressive cerebellar ataxia: A differential diagnosis of atypical parkinsonism. J. Neurol. 2019;266:522–524. doi: 10.1007/s00415-018-9115-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-018-9115-1</ArticleId>
            <ArticleId IdType="pubmed">30460451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landa J., Guasp M., Petit-Pedrol M., Martínez-Hernández E., Planagumà J., Saiz A., Ruiz-García R., García-Fernández L., Verschuuren J., Saunders-Pullman R., et al.  Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:213–232. doi: 10.1212/NXI.0000000000000916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000916</ArticleId>
            <ArticleId IdType="pmc">PMC7641326</ArticleId>
            <ArticleId IdType="pubmed">33144342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Ringelstein M., Haas J., Serysheva I.I., Komorowski L., Fechner K., Wandinger K.-P., Albrecht P., Hefter H., Moser A., et al.  Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. J. Neuroinflamm. 2016;13:278. doi: 10.1186/s12974-016-0737-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0737-x</ArticleId>
            <ArticleId IdType="pmc">PMC5078930</ArticleId>
            <ArticleId IdType="pubmed">27776522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Scharf M., Begemann N., Stöcker W., Probst C., Serysheva I.I., Nagel S., Graus F., Psimaras D., Wildemann B., et al.  Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (itpr1) in cerebellar ataxia. J. Neuroinflamm. 2014;11:206. doi: 10.1186/s12974-014-0206-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-014-0206-3</ArticleId>
            <ArticleId IdType="pmc">PMC4300617</ArticleId>
            <ArticleId IdType="pubmed">25498830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berzero G., Hacohen Y., Komorowski L., Scharf M., Dehais C., Leclercq D., Fourchotte V., Buecher B., Honnorat J., Graus F., et al.  Paraneoplastic cerebellar degeneration associated with anti-itpr1 antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2017;4:e326. doi: 10.1212/NXI.0000000000000326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000326</ArticleId>
            <ArticleId IdType="pmc">PMC5292928</ArticleId>
            <ArticleId IdType="pubmed">28203616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfugham N., Gadoth A., Lennon V.A., Komorowski L., Scharf M., Hinson S., McKeon A., Pittock S.J.  Itpr1 Autoimmunity: Frequency, Neurologic Phenotype, and Cancer Association. Rehobot Atamiwoc; Addis Ababa, Ethiopia: 2018. 294p </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5778826</ArticleId>
            <ArticleId IdType="pubmed">29379822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Tan J., Sun H., Liu Y., Guan W., Jia J., Wang Z. Anti-sox1 antibodies in paraneoplastic neurological syndrome. J. Clin. Neurol. 2020;16:530–546. doi: 10.3988/jcn.2020.16.4.530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2020.16.4.530</ArticleId>
            <ArticleId IdType="pmc">PMC7541980</ArticleId>
            <ArticleId IdType="pubmed">33029958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Do D., Gupton S.L., Tanji K., Bastien J., Brugière S., Couté Y., Quadrio I., Rogemond V., Fabien N., Desestret V., et al.  Trim9 and trim67 are new targets in paraneoplastic cerebellar degeneration. Cerebellum. 2019;18:245–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6445697</ArticleId>
            <ArticleId IdType="pubmed">30350014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Coevorden-Hameete M.H., van Beuningen S.F.B., Perrenoud M., Will L.M., Hulsenboom E., Demonet J.-F., Sabater L., Kros J.M., Verschuuren J.J.G.M., Titulaer M.J., et al.  Antibodies to trim46 are associated with paraneoplastic neurological syndromes. Ann. Clin. Transl. Neurol. 2017;4:680–686. doi: 10.1002/acn3.396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.396</ArticleId>
            <ArticleId IdType="pmc">PMC5590547</ArticleId>
            <ArticleId IdType="pubmed">28904989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larman H.B., Zhao Z., Laserson U., Li M.Z., Ciccia A., Gakidis M.A.M., Church G.M., Kesari S., Leproust E.M., Solimini N.L., et al.  Autoantigen discovery with a synthetic human peptidome. Nat. Biotechnol. 2011;29:535–541. doi: 10.1038/nbt.1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1856</ArticleId>
            <ArticleId IdType="pmc">PMC4169279</ArticleId>
            <ArticleId IdType="pubmed">21602805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Etemadifar M., Aghababaei A., Nouri H., Kargaran P.K., Mohammadi S., Salari M. Autoimmune encephalitis: The first observational study from iran. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2021:1–10. doi: 10.1007/s10072-021-05400-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-021-05400-1</ArticleId>
            <ArticleId IdType="pubmed">34328580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyer S.G., Khakoo N.S., Aitcheson G., Perez C. Case of anti-zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. BMJ Case Rep. 2020;13:e235607. doi: 10.1136/bcr-2020-235607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2020-235607</ArticleId>
            <ArticleId IdType="pmc">PMC7500196</ArticleId>
            <ArticleId IdType="pubmed">32943444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gresa-Arribas N., Planaguma J., Petit-Pedrol M., Kawachi I., Katada S., Glaser C.A., Simabukuro M.M., Armangue T., Martinez-Hernandez E., Graus F., et al.  Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86:2235–2242. doi: 10.1212/WNL.0000000000002775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002775</ArticleId>
            <ArticleId IdType="pmc">PMC4909558</ArticleId>
            <ArticleId IdType="pubmed">27170573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loehrer P.A., Bien C.I., Dusoi A.E., Timmermann L., Simon O.J. Neurexin-3α-associated autoimmune encephalitis: A case report of full recovery after rituximab therapy. Eur. J. Neurol. 2020;27:e91–e93. doi: 10.1111/ene.14481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14481</ArticleId>
            <ArticleId IdType="pubmed">32803799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inui R., Saito K., Shimomura Y., Yamashita D., Kawamoto M., Ishikawa T. Anti-ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant hodgkin lymphoma: A case report. BMC Neurol. 2020;20:355.  doi: 10.1186/s12883-020-01929-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-020-01929-4</ArticleId>
            <ArticleId IdType="pmc">PMC7513504</ArticleId>
            <ArticleId IdType="pubmed">32967629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou Y., Xu S.-H., Zhang S.-R., Shu Q.-F., Liu X.-L. Anti-yo antibody-positive paraneoplastic cerebellar degeneration in a patient with possible cholangiocarcinoma: A case report and review of the literature. World J. Clin. Cases. 2021;9:4423–4432. doi: 10.12998/wjcc.v9.i17.4423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12998/wjcc.v9.i17.4423</ArticleId>
            <ArticleId IdType="pmc">PMC8173421</ArticleId>
            <ArticleId IdType="pubmed">34141810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudero D., Guasp M., Ariño H., Gaig C., Martínez-Hernández E., Dalmau J., Graus F. Antibody-associated cns syndromes without signs of inflammation in the elderly. Neurology. 2017;89:1471–1475. doi: 10.1212/WNL.0000000000004541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004541</ArticleId>
            <ArticleId IdType="pmc">PMC5631166</ArticleId>
            <ArticleId IdType="pubmed">28878050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A., Graus F., Dalmau J., Pifarré A., Marín C., Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 1999;46:774–777. doi: 10.1002/1531-8249(199911)46:5&lt;774::AID-ANA14&gt;3.0.CO;2-N.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;774::AID-ANA14&gt;3.0.CO;2-N</ArticleId>
            <ArticleId IdType="pubmed">10553996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mascalchi M., Vella A. Magnetic resonance and nuclear medicine imaging in ataxias. Handb. Clin. Neurol. 2012;103:85–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21827882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldarçara L., Currie S., Hadjivassiliou M., Hoggard N., Jack A., Jackowski A.P., Mascalchi M., Parazzini C., Reetz K., Righini A., et al.  Consensus paper: Radiological biomarkers of cerebellar diseases. Cerebellum. 2015;14:175–196. doi: 10.1007/s12311-014-0610-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-014-0610-3</ArticleId>
            <ArticleId IdType="pmc">PMC4929983</ArticleId>
            <ArticleId IdType="pubmed">25382714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhavan A.A., Carr C.M., Morris P.P., Flanagan E.P., Kotsenas A.L., Hunt C.H., Eckel L.J., Lindell E.P., Diehn F.E. Imaging review of paraneoplastic neurologic syndromes. AJNR. Am. J. Neuroradiol. 2020;41:2176–2187. doi: 10.3174/ajnr.A6815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A6815</ArticleId>
            <ArticleId IdType="pmc">PMC7963261</ArticleId>
            <ArticleId IdType="pubmed">33093137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahta A., Vijayvergia N., Bhavsar T.M., Ward L.D. Diagnostic approach to a patient with paraneoplastic neurological syndrome. World J. Oncol. 2012;3:243–246. doi: 10.4021/wjon571w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4021/wjon571w</ArticleId>
            <ArticleId IdType="pmc">PMC5649905</ArticleId>
            <ArticleId IdType="pubmed">29147315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilmore C.P., Elliott I., Auer D., Maddison P. Diffuse cerebellar mr imaging changes in anti-yo positive paraneoplastic cerebellar degeneration. J. Neurol. 2010;257:490–491. doi: 10.1007/s00415-009-5407-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5407-9</ArticleId>
            <ArticleId IdType="pubmed">19943166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto Y., Komatsu K., Nakagawa T., Matsumoto S. Transient diffusion-weighted imaging hyperintensity of the cerebellar cortex in paraneoplastic cerebellar degeneration. Intern. Med. 2019;58:619–620. doi: 10.2169/internalmedicine.1398-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.1398-18</ArticleId>
            <ArticleId IdType="pmc">PMC6421144</ArticleId>
            <ArticleId IdType="pubmed">30210124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karmon Y., Inbar E., Cordoba M., Gadoth N. Paraneoplastic cerebellar degeneration mimicking acute post-infectious cerebellitis. Cerebellum. 2009;8:441–444. doi: 10.1007/s12311-009-0128-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-009-0128-2</ArticleId>
            <ArticleId IdType="pubmed">19727999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K.-D., Kim J.S., Park S.-H., Kim Y.K., Kim S.E., Smitt P.S. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J. Neurol. Neurosurg. Psychiatry. 2006;77:525–528. doi: 10.1136/jnnp.2005.075325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2005.075325</ArticleId>
            <ArticleId IdType="pmc">PMC2077501</ArticleId>
            <ArticleId IdType="pubmed">16543536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroiss A., Uprimny C., Virgolini I.J. Thyroid carcinoma detected by incidental (18)f-fdg uptake in a patient with progressive cerebellar syndrome. Endocrine. 2016;51:199–200. doi: 10.1007/s12020-015-0646-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-015-0646-2</ArticleId>
            <ArticleId IdType="pubmed">26077948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Wang W., Zhao Y., Cui R. Cerebellar hypermetabolism in a case of paraneoplastic cerebellar syndrome with the primary lymphoepithelial carcinoma in tonsil. Clin. Nucl. Med. 2019;44:812–814. doi: 10.1097/RLU.0000000000002657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0000000000002657</ArticleId>
            <ArticleId IdType="pubmed">31162262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer M.J., Soffietti R., Dalmau J., Gilhus N.E., Giometto B., Graus F., Grisold W., Honnorat J., Sillevis Smitt P.A.E., Tanasescu R., et al.  Screening for tumours in paraneoplastic syndromes: Report of an efns task force. Eur. J. Neurol. 2011;18:19-e13. doi: 10.1111/j.1468-1331.2010.03220.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03220.x</ArticleId>
            <ArticleId IdType="pmc">PMC3086523</ArticleId>
            <ArticleId IdType="pubmed">20880069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ropper A.H., Samuels M.A., Klein P.J.  Adams and Victor’s Principles of Neurology. McGraw-Hill Medical; New York, NY, USA: 2019. </Citation>
        </Reference>
        <Reference>
          <Citation>Mitoma H., Hadjivassiliou M., Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14. doi: 10.1186/s40673-015-0034-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40673-015-0034-y</ArticleId>
            <ArticleId IdType="pmc">PMC4641375</ArticleId>
            <ArticleId IdType="pubmed">26561527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld M.R., Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin. Neurol. 2010;30:320–331. doi: 10.1055/s-0030-1255223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0030-1255223</ArticleId>
            <ArticleId IdType="pubmed">20577938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer M.J., McCracken L., Gabilondo I., Armangué T., Glaser C., Iizuka T., Honig L.S., Benseler S.M., Kawachi I., Martinez-Hernandez E., et al.  Treatment and prognostic factors for long-term outcome in patients with anti-nmda receptor encephalitis: An observational cohort study. Lancet Neurol. 2013;12:157–165. doi: 10.1016/S1474-4422(12)70310-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70310-1</ArticleId>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czock D., Keller F., Rasche F.M., Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005;44:61–98. doi: 10.2165/00003088-200544010-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544010-00003</ArticleId>
            <ArticleId IdType="pubmed">15634032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt K.A., Sandoval K.E. Steroids and the blood-brain barrier: Therapeutic implications. Adv. Pharmacol. 2014;71:361–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25307223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T., Oishi T., Fukuoka Y., Nishikawa S., Iizuka N., Kato H. Potential effect of intravenous immunoglobulin against paraneoplastic cerebellar degeneration in progressive ovarian cancer. Gynecol. Oncol. Rep. 2020;34:100649. doi: 10.1016/j.gore.2020.100649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gore.2020.100649</ArticleId>
            <ArticleId IdType="pmc">PMC7509787</ArticleId>
            <ArticleId IdType="pubmed">33005721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu F.Q., Shang F.R., Liu J.J., Yuan H. Plasma exchange for treating anti-yo-associated paraneoplastic cerebellar degeneration: Case report and literature review. Medicine. 2020;99:e21760. doi: 10.1097/MD.0000000000021760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000021760</ArticleId>
            <ArticleId IdType="pmc">PMC7437810</ArticleId>
            <ArticleId IdType="pubmed">32872070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y., Tian X., Wang X., Xiao Z. Adverse effects of immunoglobulin therapy. Front. Immunol. 2018;9:1299. doi: 10.3389/fimmu.2018.01299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01299</ArticleId>
            <ArticleId IdType="pmc">PMC6008653</ArticleId>
            <ArticleId IdType="pubmed">29951056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flabeau O., Laurent C., Schneider S., Honnorat J., Ellie E. Spinal cord tractopathy in paraneoplastic anti-cv2/crmp5 myelitis responsive to plasma exchange. Rev. Neurol. 2021 doi: 10.1016/j.neurol.2021.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2021.04.009</ArticleId>
            <ArticleId IdType="pubmed">34247849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizenko C., Bennett J.L., Owens G., Vollmer T.L., Piquet A.L. A longitudinal, observational analysis of neuronal injury biomarkers in a case report of a patient with paraneoplastic anti-crmp5 antibody-associated transverse myelitis. Front. Neurol. 2021;12:691509. doi: 10.3389/fneur.2021.691509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.691509</ArticleId>
            <ArticleId IdType="pmc">PMC8328144</ArticleId>
            <ArticleId IdType="pubmed">34349723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chevret S., Hughes R.A., Annane D. Plasma exchange for guillain-barré syndrome. Cochrane Database Syst. Rev. 2017;2:Cd001798. doi: 10.1002/14651858.CD001798.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001798.pub3</ArticleId>
            <ArticleId IdType="pmc">PMC6464100</ArticleId>
            <ArticleId IdType="pubmed">28241090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rath J., Zulehner G., Schober B., Grisold A., Krenn M., Cetin H., Zimprich F. Real-world treatment of adult patients with guillain-barré syndrome over the last two decades. Sci. Rep. 2021;11:19170. doi: 10.1038/s41598-021-98501-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-98501-y</ArticleId>
            <ArticleId IdType="pmc">PMC8476500</ArticleId>
            <ArticleId IdType="pubmed">34580356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abboud H., Probasco J.C., Irani S., Ances B., Benavides D.R., Bradshaw M., Christo P.P., Dale R.C., Fernandez-Fournier M., Flanagan E.P., et al.  Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. J. Neurol. Neurosurg. Psychiatry. 2021;92:757–768. doi: 10.1136/jnnp-2020-325300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-325300</ArticleId>
            <ArticleId IdType="pmc">PMC8223680</ArticleId>
            <ArticleId IdType="pubmed">33649022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjivassiliou M., Grunewald R.A., Shanmugarajah P.D., Sarrigiannis P.G., Zis P., Skarlatou V., Hoggard N. Treatment of primary autoimmune cerebellar ataxia with mycophenolate. Cerebellum. 2020;19:680–684. doi: 10.1007/s12311-020-01152-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-020-01152-4</ArticleId>
            <ArticleId IdType="pmc">PMC7471147</ArticleId>
            <ArticleId IdType="pubmed">32524518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito M., Penza P., Orefice G., Pagano A., Parente E., Abbadessa A., Bonavita V. Successful treatment of paraneoplastic cerebellar degeneration with rituximab. J. Neuro-Oncol. 2008;86:363–364. doi: 10.1007/s11060-007-9479-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-007-9479-z</ArticleId>
            <ArticleId IdType="pubmed">17924058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poepel A., Jarius S., Heukamp L.C., Urbach H., Elger C.E., Bien C.G., Voltz R. Neurological course of long-term surviving patients with sclc and anti-hu syndrome. J. Neurol. Sci. 2007;263:145–148. doi: 10.1016/j.jns.2007.07.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2007.07.007</ArticleId>
            <ArticleId IdType="pubmed">17706677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294–305. doi: 10.1016/S1474-4422(02)00135-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(02)00135-7</ArticleId>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L., Graus F., Saiz A., Vilchez J.J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain J. Neurol. 2001;124:437–443. doi: 10.1093/brain/124.2.437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.2.437</ArticleId>
            <ArticleId IdType="pubmed">11157570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark E., Wurster U., Patzold U., Sailer M., Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch. Neurol. 1995;52:814–818. doi: 10.1001/archneur.1995.00540320098016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1995.00540320098016</ArticleId>
            <ArticleId IdType="pubmed">7639633</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
